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The post-transcriptional regulation of HIV-1 replication is finely controlled by 
both viral and host factors. Among the former, Rev is involved in the nuclear ex-
port of viral intron-containing mRNAs, a group of transcripts which encodes for 
viral enzymes and structural proteins, but also constitute the viral genome that 
will be encapsidated into nascent virions. 
To avoid the nuclear retention of these intron-containing transcripts, Rev en-
gages an alternative export route which ultimately involves the CRM-1 export 
factor; during this process Rev requires the concerted action of several host fac-
tors but the details of its interactions are still not fully understood. To dissect this 
pathway a novel proteomic approach for the immunoprecipitation of the viral 
RNA was developed in our laboratory : we thus  identified the nuclear matrix 
protein MATR3 as a  Rev co-factor which was recruited after mRNA biogenesis 
during this process (Kula et al., 2011, 2013). We could assess that MATR3 acts in 
the post-transcriptional steps of viral replication and we could demonstrate its 
role as a Rev-cofactor during the nuclear export of viral mRNAs. 
To establish the functional role of MATR3 during acute viral infection we modu-
late its levels in Jurkat cells by both knockdown or overexpression. We found 
that, while MATR3 depletion resulted in the drastic reduction of viral replication, 
its overexpression leads to enhanced viral particle production. We applied the 
same approach to primary PBLs and obtained a similar result concluding that 
MATR3 is a positive regulator of viral replication. 
To investigate a possible role for MATR3 in the establishment of viral latency we 
depleted MATR3 from J-Lat cells, a well-established model of latency. We ob-
served that MATR3 depletion did not impede  transcriptional reactivation of the 
integrated provirus upon TNFα stimulation, but strongly impaired intracellular 
viral protein production and full viral rescue. 
This observation demonstrated that MATR3 depletion affects the post-
transcriptional steps of latency reversal suggesting that this factor could play a 
crucial role during the maintenance of latency.  
Since most of the attempts done with Latency Reversal Agents (LRAs), an hetero-
geneous  group of drugs proposed to restore viral transcription, failed to induce 
full reactivation of the latent provirus (Darcis et al., 2015; Spina et al., 2013) we 





in latently infected cells and we suppose that MATR3 could represent a limiting 
factor to this process. We confirmed that MATR3  was almost undetectable in 
resting PBLs but could be promptly upregulated upon cellular activation. MATR3 
was not induced by treatment with LRAs, such as SAHA or Romidepsin within PBL 
from healthy donors and HIV-infected patients. 
We propose that the restoration of proper MATR3 levels within latently infected 







THE HIV-1 VIRUS: GENOME, STRUCTURE AND LIFE 
CYCLE 
HIV-1 AND AIDS 
The immunodeficiency virus type 1 (HIV-1) is the causative agent of the acquired 
immunodeficiency syndrome (AIDS), a systemic disease characterized by the 
dramatic drop in CD4+ T lymphocyte count which ultimately leads to the loss of 
immune system function. 
Although the discovery of HIV-1 virus dated at more than 30 years ago, AIDS is 
still a mayor public health concern worldwide with a high burden of mortality 
and morbidity in developing countries (Barré-Sinoussi et al., 1983; Gallo et al., 
1983). It has been estimated that around 35million people are HIV-1 infected and 
2,3 million of new cases have been diagnosed only in 2012. Although the abso-
lute number of new HIV infections is still high, it represents an historical mini-
mum with a negative trend in morbidity which is remarked also by the huge de-
crease in death cases during the last decade (ECDC  annual epidemiological re-
port 2014). 
Success in prevention and treatment of AIDS is due to the development of an ef-
ficient antiretroviral therapy based on the combined administration of drugs 
which target different phases of the viral life cycle. Constant adherence to the 
therapy results for the patient in the reduction of plasma viremia which is 
dropped to undetectable levels.  
Despite its high efficiency in controlling the progression of the disease, the anti-
retroviral therapy is a life-long treatment which is not able to eradicate the viral 
infection. The therapy interruption results in the rebound of viral replication 
which is due to the existence of a “viral reservoir” in which the virus could re-
main dormant for an undefined time frame. 
The existence of a viral reservoir constitute the major obstacle to HIV-1 eradica-
tion since the actual therapy are not able to target those cells which remained 
unaffected by treatment and invisible by the immune system. Currently, the de-
velopment of a strategy able to target the viral reservoir represent the major 






HIV-1 belongs to the family of Retroviridae  (genus lentivirus) and its genome is 
based on 2 identical molecules of single-stranded RNA (+); each strand consists 
of about 9kb and carries a 5’CAP and a 3’ polyA-tail. 
HIV-1 genome contains 3 major structural genes named gag, pol and env which 
are shared by the other members of the Retroviridae family; moreover it con-









The gag gene encodes for a 55 kDa polyprotein then cleaved by the viral prote-
ase into the 3 structural proteins composing the virion: the p24 constitute the 
nucleocapsid, the  p17 is the major component of the matrix while the p15, 
processed in p6 and p7, helps in the proper assembly of the structure. 
The pol gene encodes for the viral enzymes: the reverse transcriptase (RT), a 
DNA-polymerase RNA-dependent which create a double-stranded DNA molecule 
from the RNA viral template, the integrase (IN) which catalyse the insertion of 
the viral genome within the host cellular DNA, and the protease (PR) which al-
lows the maturation of both viral polyproteins and budding virions. 
The env gene encodes for the two glycoproteins, gp120 and gp41, which form 
the spikes exposed on the external surface of the virion: these structures are re-
HIV-1 genome organization – from Sakuma et al., Biochemical Journal 2012 
The viral genome encodes three structural and six non-structural genes flanked by the LTRs. The 
Gag precursor consists of matrix (MA), capsid protein (CA), nucleocapsid protein (NC) and p6. 
The Pol gene encodes for reverse-transcriptase (RT), integrase (IN) and protease (PR). The 
envelope glycoprotein of HIV-1 encodes the polyprotein envelope precursor (gp160), which is 
eventually cleaved by PR to generate gp120 (SU) and gp41 (TM) domains. The RRE located with-








sponsible for the interaction between the virus and the host target cell by medi-
ating the binding to receptors and co-receptors.  
The accessory proteins are involved in a variety of functions within the viral life 
cycle, ranging from the enhancement of transcription to the modulation of the 
host immune response. 
The Tat gene (Trans-Activator of Transcription) is constitute by two separate ex-
ons and encodes for a small protein (86-101 amino acids depending on the viral 
strain) which is crucial to enhance the transcription of the integrated provirus 
also thanks to its broad interactome (Gautier et al., 2009). The Tat protein binds 
the cis-acting elements TAR located downstream of the initiation site for tran-
scription and promotes the assembly of the RNA Pol II transcription complex 
(Brady and Kashanchi, 2005); moreover Tat enhance transcripts elongation by 
promoting the activity of the p-TEFb factor, but also by recruiting some cellular 
histone acetyltransferases to remodel the chromatin at the LTR site (Benkirane 
et al., 1998; Zhu et al., 1997). 
The Rev gene produces a 20 kDa protein which shuttles between the nucleus and 
the cytoplasm to mediate the export of intron-containing viral transcripts; this 
specific class of viral mRNAs are targeted by Rev because of the presence of  the 
Rev-Responsive Elements (RRE), a sequence located at the 5’ within the env gene 
which is bound by the protein to enhance their export. 
The Nef gene (Negative Expression regulatory Factor) encodes for a phosphopro-
tein involved in the regulation of viral infectivity and in the evasion from the host 
immune response: after infection of the target cell, Nef, along with the Vpu viral 
factor, modulate the surface level of the CD4 receptor to avoid both the super-
infection by other virions and the cytotoxic activity of CD8+ T lymphocytes. Re-
cently, Nef was also reported to counteract the activity of the host restriction 
factor SERINC5, a cellular transmembrane protein which, if incorporated into 
nascent virion, render the particles less infectious. Nef is able to redirect the cel-
lular localization of SERINC5 to the endosomal compartment to avoid its inclu-
sion within the nascent virions (Rosa et al., 2015). 
The Vif gene encodes for a small regulatory factor which strongly counteracts the 
cellular antiviral response during the very early phase of infection: Vif induces 
the proteasomal degradation of the cellular citidine deaminase APOBEC3G which 






The Vpr factor plays an important role in the formation of the pre-integration 
complex and has also been linked to the regulation of the cell cycle and the 
apoptosis in the infected cells (Planelles and Barker, 2010). Moreover Vpr was 
shown to directly interact with the transcription factor TFIIB and to be putatively 
able to bind DNA: thus Vpr can also contribute to induction of viral basal tran-
scription at the LTR (Agostini et al., 1996; Zhang et al., 1998). 
STRUCTURE OF THE VIRAL LTR 
The viral Long Terminal Repeat (LTR) are non coding sequences of approximately 
640bp in length located both at the 5’ and 3’ end of the provirus; each LTR con-
sists of 2 Unique sequences (U3 and U5) and one Repeat sequence (R). 
The U3 region of the 5’LTR contains the viral promoter with all the functional se-
quences to allow the initiation of transcription by the cellular RNA polymerase II: 
enhancer elements surround the TATA box while 2 binding sites for Nf-KB and 3 
for Sp-1 ale placed in tandem immediately upstream of the TATA box. 
The region immediately upstream the NF-kB binding site, also known as the 
“modulatory region”, is rich in cis-acting binding sites for cellular factors respon-
sible both the repression and the activation of the viral LTR (Jones and Peterlin, 
1994; Pereira et al., 2000) 
The TAR element is a 26 nucleotide sequence located downstream the initiation 
of transcription site, within the R region, and forms a highly stable stem-loop 
structure characterized by stems, pyrimidine-rich bulge and loops; this structure 
is recognized by Tat and essential for transcriptional transactivation: mutations 
analysis which disrupt the TAR base pairing were shown to abolish the Tat-driven 
LTR transcription (Selby et al., 1989). 
At the edge of both the LTRs  are located the att sites, targeted by the viral inte-
grase to insert the provirus into the host genome; the packaging signals (PSI) re-
quired for the incorporation of the viral genome into the nascent virion are also 
located within the LTR. 
STRUCTURE OF THE VIRION 
The HIV-1 virion is a icosahedral enveloped particle of approximately 145nm. 
The external phospholipid envelope is derived by the host cell membrane during 





coprotein spikes composed by heterodimers of gp120 and gp41: these structures 
mediate the interaction of the virus with the host target cells by recognizing and 
binding the cellular receptors and co-receptors present at the cellular mem-
brane. 
More internally in the structure there is the matrix formed by the myristoylated 
p17 protein, which allows the correct anchoring of the envelop to the viral cap-
sid. 
The most internal part of the virion is the nucleocapsid, a conical structure of 
p24, which contains both the viral genome associated with the p6 and p7 pro-
teins and the viral enzymes of reverse transcriptase and integrase.  
This final structure characterizes the mature virion and is generated by a process 
of maturation performed by the viral protease, which cleaves the multimeric gag 
polyprotein to allow the proper assembly of the different layers of matrix and 
nucleocapsid. 
VIRAL LIFE CYCLE 
The first contact between the virus and the target cell is established through the 
interaction of the viral gp120/gp41 heterodimer with the cellular CD4 receptor 
expressed by the cells of the monocytic-machrophage lineage  and by lympho-
cytes. 
The binding with the receptor causes a profound rearrangement in the structure 
of these proteins and lead to the exposition of those domains responsible for the 
binding to the cellular co-receptors: the usage of CCR5 as a co-receptor defines 
the HIV-1 R5-tropic strains,  while the preference for the CXCR-4 co-receptor 
characterizes the HIV-1-X4-tropic strains. 
The interaction with the co-receptor causes another structural change in the en-
velope spikes that induces the exposure of a portion of the peptide which is es-
sential to allow the fusion of the viral and cellular membranes and the release of 
the viral nucleocapsid into the cellular cytoplasm. 
Once in the cytoplasm, the nucleocapsid undergoes a process of disassembly 
called uncoating, which ends with the  release of the viral genome, which is fi-
nally available for the subsequent reverse transcription: the viral RT uses the 





with the integrase (Farnet and Haseltine, 1991) and likely with p17 and Vpr (Bu-
krinsky et al., 1993) to form the pre-integration complex (PIC). 
The movement of the PIC through the cytoplasm depends on the association 
with actin (Bukrinskaya et al., 1998)  and its import into the nucleus occurs 
through the nuclear pore complex, a process which seems to be mediated by the 
Vpr factor (De Rijck and Debyser, 2006). 
The integration of viral genome into the host DNA is mediated by the viral inte-
grase with the cooperation of several cellular factors: among them the nuclear 
protein LEDGF/p75 was found to interact with the integrase and to help its an-
choring to the chromatin (Llano et al., 2004), while the DNA binding protein 
HGMA I seems to induce chromatin remodelling to facilitate the integration (Mil-
ler et al., 1997). 
Transcription of the viral genes is performed by the RNA polymerase II starting 
from the viral promoter at the LTR and requires the trans-activator Tat to en-
hance the assembly of the complex of initiation of transcription and the recruit-
ment of the elongation factors (Kao et al., 1987; Tahirov et al., 2010). 
The immature full-length pre-mRNA undergoes a splicing process to generate 3 
different classes of transcripts: the unspliced (US; 9kb) the singly-spliced (SS; 4kb) 
and the multiply-spliced (MS; 2kb) transcripts. 
The US  and the SS mRNAs encodes mostly for structural proteins and enzymes, 
but also, in the case of the US transcripts, serves as the viral genome to be en-
capsidated into new virions; the MS mRNAs are translated into regulatory factors 
such as Tat and Rev, crucial to allow full viral gene expression by acting both in 
the transcription and export of viral mRNAs. 
The expression of the different viral genes is temporally distinct: regulatory 
genes (Tat, Rev and Nef) are translated during the early phase of the viral life cy-
cle because of their requirement to allow the late phase genes expression by in-
creasing the efficiency of transcription (Tat) or the mRNAs’ nucleo-cytoplasmic 
export (Rev). 
Once produced, the viral transcripts exploit different pathways to be exported to 
the cytoplasm: MS mRNAs use the same pathway of cellular ones, while the US 
and the SS transcripts need the presence of Rev to overcome the cellular restric-





The production of viral protein exploits the host cell translation machinery. 
A first block to the initiation of translation is given by the presence of several 
highly structured motifs present at the 5’UTR of both US and MS transcripts: to 
overcome this block is crucial the RNA helicase DDX3 which binds the 5’UTR and 
recruits the factor eIF4G and PABP  to allow the proper assembly of the pre-
initiation complex and to enhance the initiation of translation (Soto-Rifo et al., 
2012). 
The initiation of translation of US-mRNAs can occur both in a CAP-dependent or 
IRES-dependent manner (Brasey et al., 2003; Ricci et al., 2008), since two internal 
ribosomal entry sites are present at the 5’UTR and within the gag coding se-
quence; the CAP-dependent pathway is preferred  during the first 48hours after 
infection, while the IRES-dependent one is predominant at a later time point or 
under conditions of translation downregulation (Amorim et al., 2014). 
The translation of US mRNAs needs to be finely regulated to guarantee the main-
tenance of a proper pool of not-translated US transcripts to be enclosed within 
the nascent virion as genomic DNA. The Rev protein was proposed to play a cru-
cial role in this process in a way tightly related to its concentration: it was sug-
gested that, when low levels of Rev are available, they are mostly bound to the 
DDX3 host protein which, ultimately, forms a complex with the US transcripts to 












The viral factors Env and Vpu are translated on the rough ER: the glycoprotein 
Env is inserted co-translationally into the ER membranes, is glycosilated and as-
sembles into trimeric complex, which are then cleaved to separate the gp120 
subunit from the transmembrane  gp41. 
The Env trimeric complex is shuttled to the plasma membrane through the ve-
sicular transport and the protein spikes are inserted within the cellular mem-
brane where the nascent virion is assembled. 
HIV-1 life cycle – from Coiras et al.; Nat. Rev. Microbiol. 2015 
After the initial binding to the target cell, the viral genome is relased into the cytoplasm and 
converted in a molecule of dsDNA, which integrates within the host genome. The viral gene 
expression relies on the host cellular machinery for viral mRNA transcription and translation. 
Once translated, the viral proteins and the viral genome start accumulate at the plasma mem-







The Gag protein and the Gag-Pro polyprotein concentrate at the plasma mem-
brane and it was proposed that a crucial protein level, known as “cooperative 
threshold”, is required to trigger the activation the assembly process which begin 
with the interaction between the MA domain of Gag with the plasma membrane 
(Perez-Caballero et al., 2004; Yadav et al., 2012) and with the viral Env protein. 
The Gag and the Gag-Pro proteins alone are able to orchestrate all the events re-
quired for the assembly of the nascent virion and particularly the CA domain was 
proposed to mediate all the processes: indeed it was shown that mature CA has 
the capacity to assemble into viral particle in vitro (Ehrlich et al., 1992). 
The NC domain of Gag is able to bind the PSI sequence within the viral genome 
and thus is responsible to ensure its encapsidation within the virion (Rein et al., 
2011). 
The final release of the virion from the plasma membrane is mediated by the 
Host Endosomal Sorting Complexes Required for Transport machinery (ESCRT);  
after budding the viral protease cleaves Gag into the several components to al-
low the formation of the mature structure of the virion with a proper assembled 






EXPORT OF THE VIRAL MRNAS 
 
VIRAL MRNA EXPORT 
Upon transcription at the viral LTR, a full length 9kb transcript is generated and 
processed by the cellular splicing machinery to create 3 different class of mRNA: 
fully spliced, singly spliced and unspliced. 
Fully spliced mRNAs encodes for the 3 regulatory protein Tat, Rev and Nef which 
are also known as “early phase genes” because of their requirement to allow full 
viral gene expression. Immediately after their processing these group of tran-
scripts are exported to the cytoplasm by the same pathway used by cellular 
mRNAs, which involves the recruitment of Nxf-1 and of the Trex complex to al-
low the passage through the Nuclear Pore Complex (NPC). 
The presence of introns in the mature form of singly spliced (SS) and unspliced 
(US) transcripts impede their export through the same pathway exploited by fully 
spliced mRNAs; these groups of transcripts encoding for structural protein and 
enzymes are called “late phase genes” and their  retention within the nucleus 
would be an obstacle to full viral replication. 
To overcome nuclear retention and degradation of intron-containing transcripts, 
the Rev protein is essential. The presence of a nuclear localization signal allows 
Rev to be imported into the nucleus where it targets these mRNAs by binding the 
Rev-Responsive Element (RRE), a sequence present within the 5’ of the Env gene 
(Fernandes et al., 2012; Malim et al., 1990). Thus Rev engages these viral mRNAs 
for an alternative route of nuclear export which ultimately involves the Chromo-
somal Maintenance 1 (Crm-1) export factor. 
Due to its small dimension Rev acts as an adaptor protein in the interaction of 
the Rev-RNA complex with the cellular factor Crm-1, a karyopherin present in the 
nuclear export complex. 
Crm-1 (also known as Exportin-1) is responsible for the nucleo-cytoplasmic ex-
port of cellular proteins and some cellular RNAs such as the ribosomal ones 
(Okamura et al., 2015); it binds the Ran-GTP in the nucleus and through the hy-
drolysis of the GTP into GDP is able to catalyze the export of a cargo to the cyto-
plasm most likely through the interaction with nucleoporins such as Nup98 and 











To be targeted by Crm-1, the cargo needs to have a specific Nuclear Export Signal 
(NES) based on a leucine motif (or on other hydrophobic residues): even if the 
NES present on Rev is unconventional, it still allows the recognition and binding 
(Güttler et al., 2010; Paraskeva et al., 1999). 
Usually Crm-1 binds the cargo in a monomeric form but the EM reconstruction of 
the complex with Rev-RNA showed unambiguously  that, in this specific case, 
Viral mRNAs export – from Okamura et al.; Genes 2015 
HIV-1 spliced transcripts are exported through the canonical cellular export pathway (left pan-
el); intron-containing transcripts are exported through an alternative pathway involving the 







Crm-1 is present as a dimer and it was proposed that the dimerization functions 
increases the affinity for Rev’s unconventional NES (Booth et al., 2014). 
In this view, the unusual dimerization of this factor is essential to the export of 
Rev-dependent mRNAs and the inability to dimerize would constitute a limit to 
full viral replication: in line with this idea, comparative sequence analysis of hu-
man and murine Crm-1 showed that the 7 amino acids of difference between the 
two proteins resides in Crm-1’s dimer interface and this could provide a possible 
explanation for the defect in viral Gag protein production in murine cells (Sherer 
et al., 2011). 
The presence of multiple NES on the Rev oligomer would suggests the existence 
of a panel of equivalent configurations for the complex but the binding possibili-
ties are limited by steric effects due to Crm-1’s large size: in fact binding of one 
Crm-1 subunit  to a NES drastically reduces the possible orientations that the 
second Crm-1 could use to bind another NES (Booth et al., 2014; Daugherty et 
al., 2010a).  
Once the Rev-RNA complex translocates to the cytoplasm, Rev dissociation from 
the mRNAs occurs by a still unknown mechanism; different modes have been 
proposed, between the most likely there is the competition with nuclear import 
machinery for the NLS present in the same motif for RNA binding and the forced 
ejection of Rev by the ribosome: in any case cellular factors such as helicases are 
believed to help in complex disassembly (Fankhauser et al., 1991; Hadian et al., 
2009; Kutluay et al., 2014; Naji et al., 2012).  
THE REV PROTEIN 
The rev gene is transcribed early during the viral life cycle into a completely 
spliced mRNA and is translated into a small protein with dimensions ranging 
from 96 to 129 amino acids in patients (in most cases either 116 or 123 amino 
acids). 
It contains a bipartite Oligomerization Domain (OD), an Arginine-Rich Motif 
(ARM) and a Nuclear Export Sequence (NES). 
The ARM domain is an arginine-rich sequence which serves also as a nuclear lo-
calization signal (NLS). The ARM is responsible for the initial binding with the RRE 
on viral transcripts and leads to the recruitment of additional Rev monomers to 
form the final Rev-RRE complex; the interaction between Rev monomers occur 





the Rev shuttling between the nucleus and the cytoplasm, binds the Crm-1 to as-
sure the mRNAs export activity; moreover the NES domain was supposed to be 
critically important also for other activities such as the degradation of Tat, pro-












The Rev protein has a well-established function in the export of intron-containing 
viral mRNAs and viral vectors, defective for Rev, shows impaired infectivity. The 
protein level of Rev are finely regulated by a negative feedback loop: a high con-
centration of Rev increases the rate of export of unspliced transcripts thus reduc-
ing the amount of RNAs available for complete splicing and, as a consequence 
reduces the levels of Rev expression (Felber et al., 1990). 
Different research groups reported a discrepancy between the fold increase in 
cytoplasmic accumulation of unspliced RNAs and in their protein products in 
Rev structural organization and ARM/Stem loop IIB complex- from Rausch and Grice; Viruses 
2015 
A) Rev organization according to primary sequence and 3D structure; the bipartite oligomeriza-
tion domain (OLIGO) and the nuclear localization signal/RNA binding domain (NLS/RBD) are 
shown in green and blue, respectively. The C-terminal domain of Rev, which houses the nuclear 
export signal (NES) is intrinsically disordered. 
B) ARM peptide in complex with stem-loop IIB model RNA.  ARM binds in the RNA major groove; 







presence and absence of Rev (Emerman et al., 1989; Perales et al., 2005): in 
presence of Rev, a few-fold increase in the rate of cytoplasmic RNA was associ-
ated to a much stronger accumulation of viral protein. These observation sug-
gested an additional role for Rev in the enhancement of RNA translation; this hy-
pothesis was reinforced by the report of a direct interaction between Rev and 
the polysomes (D’Agostino et al., 1992; Groom et al., 2009b). Moreover, Rev was 
supposed to have a role also during the assembly of nascent virions by its direct 
involvement in the packaging of the viral genome (Groom et al., 2009b). 
Even if the focus on Rev research was mostly  put on its role on export, as fre-
quently observed for retroviral factors, a single protein could fulfil a wide range 
of tasks and be involved in different events during the viral replication; thus the 
Rev protein could exert a number of functions which of them are still not fully 
described. 
REV-RRE INTERACTION 
The RRE is a highly structured sequence consisting of 242 nucleotides at the 3’ of 
the HIV genome within the Env gene. It exists in two conformational states of 4 
or 5 stem loops (since stem III and IV could be fuse as a single stem loop); both 
conformations are functional for Rev binding although they were shown to be 
different in the efficiency of mRNA export activity, with the 5 harpin structure 
displaying the higher export activity (Heaphy et al., 1990; Olsen et al., 1990; 
Rausch and Le Grice, 2015; Sherpa et al., 2015).  
 
 










As deduced from mutational studies (Huang et al., 1991; Jayaraman et al.; Malim 
et al., 1989; Tiley et al., 1992), the RRE carries three major sites for Rev binding: 
Stem IA, Stem IIB and the Junction between Stem IIABC . 
The three-dimensional model of RRE derived from the Small Angle X-ray Scatter-
ing (SAXS) shows an “A-shape” folding with Stem IA and Stem IIB close in space, 
suggesting that a Rev dimer may bind simultaneously to the two sites; taking ac-
count of the existence of different RRE conformers the structure depicted may 
reflect the solution  average of multiple structures (Fang et al., 2013). 
Secondary structures of HIV-RRE - from Rausch and Grice; Viruses 2015  
A) RRE 5-stem structure. Established Rev-binding sites at the stem IIB, the stem-loop II junction 
and the stem IA are indicated in grey ovals. 
B) Comparison of the 5 and 4-stem structures. Differences between the two models are limited 
to the base pairing patterns of nucleotides comprising stem loop III and IV, and stem loop III/IV 







The Arginine-rich motif (ARM) of Rev is responsible for the interaction with the 
RRE: the high affinity binding of the ARM to the Stem IIB is an anchor point for 
the recruitment of six Rev molecules on the RRE sequence till the formation of 
the complete Rev-RRE ribonucleoprotein complex (RNP) identified as a Rev 
hexamer on the 242nt RRE (Daugherty et al., 2010b).  
The Rev’s ARM can use several aminoacidic residues to interact with different 
binding sites on the mRNA and the interaction mostly rely on RNA structure and 
ARM orientation than on nucleotide sequence (Jayaraman et al., 2015): the high 
degree of Rev-RRE complex plasticity may represent the key of the functional ro-
bustness to mutations in the Rev sequence. 
After the initial binding to the Stem IIB, Rev oligomerization on the RRE was pro-
posed to continue with the formation of a dimer to bind  the Junction IIABC; then 
the binding of additional Rev molecules proceed across the Stem IA till the for-
mation of the Rev hexamer (Bai et al., 2014). 
 It’s still unclear if, to prevent the binding of additional Rev molecules to the viral 
RNA, the negative feedback mechanism which regulate Rev concentration is im-
plicated, or if cellular factors, such as the hnRNPs, fulfil this task by directly bind-
ing the viral RNA (Cochrane et al., 2006; Felber et al., 1990). 
The Rev-Rev interaction occurs via the bipartite, hydrophobic OD domain and 
could lead to at least 3 different orientation of the Rev-Rev complex and this 
plasticity is useful to recognize the different possible Rev-RRE complex structures 
(Jayaraman et al.). 
CELLULAR FACTORS INTERACTING WITH REV  
The activity and localization of Rev are largely dependent on its interaction with 
a variety of cellular factors: Rev’s interactome has been studied both experimen-
tally and computationally to understand the molecular basis of the host-virus in-
teraction and of the cellular restriction to viral infection (Brass et al., 2008; König 
et al., 2008; Trono and Baltimore, 1990). 
Post translational modification of Rev such as phosphorylation and methylation 
are carried out by CK2 (Meggio et al., 1996) and PRMT6 respectively (Invernizzi 
et al., 2006)  to influence or regulate its activity. 
Apart from chemical modification, also some cellular proteins can influence Rev 





NLS to induce it’s nuclear translocation and factors such as HIC1 (Human I-mfa 
domain Containing Protein) and NAP1L1 (Nucleosome Assembly Protein 1) have 
been shown to participate to this process (Cochrane et al., 2009; Gu et al., 2011; 
Henderson and Percipalle, 1997). In particular the interaction between Rev’s NLS 
and HIC1 have been shown to inhibit Importin B-mediated nuclear import of Rev, 
but not transportin-mediated one suggesting that the spatial localization of Rev 
could be regulated in alternative ways (Gu et al., 2011). 
To allow the export of viral US-mRNAs Rev takes advantage of the interaction 
with several host factors: the recruitment of the CRM-1-Ran GTP complex allows 
the translocation of the Rev-RNP complex through the nuclear pore; other fac-
tors involved in this process are the eukaryotic initiation factor-5A (eIF-5A), 
which induces the interaction between Crm-1 and the nucleoporins (Ruhl et al., 
1993), and the helicase DDX3 (or DDX1 in astrocytes) which help the passage of 
the RNP complex through the pore(Fang et al., 2005; Yedavalli et al., 2004). 
Other proteins belonging to the RNA helicases family have been shown to inter-
act with Rev and to affect HIV replication by influencing the mRNA metabolism: 
among them, DDX3 seems to be implicated in mRNA translation while DDX5 and 
DDX17 affect both the amount and the export of viral transcripts suggesting a 
potential involvement in transcription, splicing or export (Naji et al., 2012). 
THE REV EXPORT COMPLEX 
To better characterize the involvement of host factors in the Rev-mediated nu-
clear export and to identify novel cellular interactors of the Rev-RNA complex, an 
approach based on the immunoprecipitation of the MS2-tagged viral RNA (Mai-
uri et al., 2011) coupled to a mass spectrometry analysis was developed in our 
laboratory. Through this approach it was possible to identify  the PTB-associated 
Binding Factor (PSF) and Matrin3 (MATR3) as novel components of the Rev-RNA 
RNP complex (Kula et al., 2011a). 
A more detailed analysis of this complex revealed that while MATR3 directly 
binds to PSF, its interaction with Rev occurrs in a RNA-dependent manner since it 
was lost upon treatment with the RNAse (Kula et al., 2013a). 
Moreover, it was possible to determine that, while PSF and Rev contacted the 
nascent mRNA at the site of transcription, MATR3 was recruited in a second 
moment to most probably enhance the Rev-mediated export of viral mRNAs (Ku-





PSF binding to the INS sequences of the HIV-RNA was shown to stabilize the viral 
transcripts (Zolotukhin et al., 2003) and both PSF and MATR3 were previously 
implicated in the nuclear retention of hyperedited RNAs (Zhang and Carmichael, 
2001): the documented involvement of PSF and MATR3 in mRNA metabolism 
make reasonable to hypothesize that their interaction with Rev is finalized to 
avoid the nuclear retention of viral transcripts and that they are recruited by Rev 
to the alternative route of viral mRNA export.  
THE NUCLEAR MATRIX PROTEIN MATR3 
The nuclear matrix protein MATR3 binds the inner nuclear membrane and, along 
with the other matrix proteins, forms a fibrogranular network involved in 
chromatin organization, genome replication and gene expression (Bode et al., 
2003).  
Concerning its sub-cellular localization, MATR3 is mainly found in the insoluble 
nucleoplasm with the exception of the nucleolus even if, by biochemical 
fractionation, it was shown that it’s possible to find MATR3 also in the soluble 
nucleoplasmic fraction and, at lower levels, in the cytoplasm (Coelho et al., 2015; 
Hibino et al., 2006; Zeitz et al., 2009). 
MATR3 is an highly conserved 125 kDa protein which contains a bipartite nuclear 
localization signal (NLS), two zinc-finger domains (ZF) and two RNA-recognition 
motifs (RRM); the remaining disordered region of the protein is supposed to 
mediate protein-protein interactions, as in the case of the PTBP1- RRM 
Interaction Motif (PRI), a seven amino acid sequence found within this region 
which is responsible for the interaction with the splicing factor PTB (Coelho et al., 
2015; Hibino et al., 2006). 
The two ZF domains mediate the interaction with the cellular DNA and the 
deletion of both of them is required to abolish the DNA binding. 
The two RRM domains are responsible for the binding to the target RNA and it 
has been suggested that the RRM preferentially recognize the AUCUU motif as 
the optimal RNA target site (Coelho et al., 2015; Hibino et al., 2006).  
Several proteins have been reported to interact with MATR3 and, of note, the 
majority of them are factors involved in RNA binding and metabolism such as 
PSF, PTB and p54nrb. Also thanks to its broad spectra of interactors, MATR3 was 
proposed to exert a number of functions ranging from the regulation of mRNA 





in viral mRNA export (Kula et al., 2011a, 2013a; Yedavalli and Jeang, 2011) and in 
the DNA damage response (Salton et al., 2010). 
It was reported that Double Strand Breaks (DSBs) induces MATR3 
phosphorylation at the Serine208 by the ATM kinase and this modification was 
proposed as a trigger event to induce the DNA damage response: upon 
phosphorylation, MATR3 forms a complex with PSF and p54nrb, and their 
interaction with MATR3 was proposed to be crucial for the correct recruitment 
and release of the two factors at the damaged site (Salton et al., 2010).  
MATR3 was frequently associated to different processes in RNA metabolism. 
Transcriptome-wide analysis performed in MATR3 depleted HeLa cells, showed 
that MATR3 can regulate alternative splicing with or without the cooperation of 
PTB (Coelho et al., 2015), while MATR3 depletion  in U2OS cells was associated to 
the altered expression of 77 genes. In particular it was shown that upon MATR3 
knockdown the levels of these transcripts were reduced and the effect was 
associated to a reduced RNA stability while a transcriptional effect was excluded 
(Salton et al., 2011). 
Mutations in MATR3 sequence have been associated to the development of a 
progressive miopathy called Vocal Cord and Pharyingeal weakness with Distal 
Myopathy (VCPDM) (Senderek et al., 2009) and, more recently, to the familiar 
form of Amiotrophic Lateral Sclerosis (ALS) (Johnson et al., 2014). 
Further investigation on the pathological role of ALS-associated mutations of 
MATR3 sequence suggested that these mutations altered MATR3 interaction 
with several components of the cellular Transcription and Export protein 
complex (TREX) thus leading to altered global mRNA nuclear export (Boehringer 
et al., 2017). 
MATR3 was also identified as a positive regulator of HIV-1 replication as it is re-
quired to allow full viral gene expression by enhancing Rev-mediated export of 
US-mRNAs (Kula et al., 2011a, 2013a; Yedavalli and Jeang, 2011); moreover, it 
was observed that MATR3 depletion strengthens  the antiviral activity of  the po-







LATENCY: DISCOVERY, DEFINITION AND COMPOSITION OF THE VIRAL RESER-
VOIR 
In the late 1990’s different clinical investigation on cohorts of HIV+ patients re-
ported that the administration of the Highly Active Antiretroviral Therapy 
(HAART) for several years was not sufficient to eradicate the virus: upon treat-
ment discontinuation the plasma viremia recurred in few weeks (Palmer et al., 
2008; Zhang et al., 2000). 
At the same time it was demonstrated that the virus can establish a latent phase 
within a small fraction of infected cells: in HAART treated patients it was identi-
fied a subset of cells which contained a copy of the integrated provirus (~1 inte-
grated copy of HIV in 1x10^6 CD4+T cells) but didn’t express viral particles (Chun 
et al., 1997; Finzi et al., 1997; Wong et al., 1997). These cells carrying a silent 
provirus were found to be responsible for the rebound of plasma viremia after 
drug interruption and were defined as the “viral reservoir” established very early 
during infection. Notably, a fraction of these infected cells contained a defective 
virus whose expression couldn’t be rescued and thus their contribution to the 
clinically significant pool of the viral reservoir is null.  
Latently infected cells are thus defined as the cells which carry at least one copy 
of integrated HIV DNA; the provirus is silent but inducible and, upon cellular acti-
vation, is able to produce and release full viral particles. 
Some authors reported that, on the contrary to current opinion, latently infected 
cells were capable of transcribing low levels of HIV RNA and prevalently 
unspliced viral transcripts were detected (Lassen et al., 2004; Pasternak et al., 
2009). It is unclear if the rate of  viral mRNA transcription was sufficient to 
achieve viral protein production in latent cells; however, the detection of viral 
transcripts and the absence of full virions suggested the existence of multiple 
barriers to productive infection within the cells of the viral reservoir. 
Several cell types were identified as components of the viral reservoir (Chomont 
et al., 2009; Palmer et al., 2008); nevertheless the resting central memory CD4+ T 
lymphocytes were proposed as the most representative ones and are character-
ized by the lack of activation markers such as CD25 and CD69 (Chun et al., 1995; 





and NF-kB, which contribute to the maintenance of the proviral  transcriptional 
silencing (Colin and Van Lint, 2009). 
The virus may persist also in macrophages (Igarashi et al., 2001) and in stem or 
progenitor cells (Carter et al., 2010); due to their short half life dendritic cells and 
monocytes seems  unlikely to represent an important part of the reservoir even 
if, upon their differentiation into macrophages, they can contribute to the forma-
tion of local reservoirs in specific body districts such as the central nervous sys-
tem (Burdo et al., 2010; Hasegawa et al., 2009). 
ORIGIN AND PERSISTENCE OF THE RESERVOIRE 
The molecular details which lead to the establishment of a viral reservoir early 
during the infection is still a matter of debate. Latently infected cells may arise 
from the infection of activated cells that, after viral integration, return to a rest-
ing state, as suggested by the observation that memory T cells are the major 
component of the viral reservoir (Chun et al., 1995, 1997). However, the infec-
tion could also occur directly in resting T cells as observed in vitro (Agosto et al., 
2007; Plesa et al., 2007): this event is even more likely to occur in vivo in a cyto-
kine rich environment supported by the presence of dendritic cells and macro-
phages (Eckstein et al., 2001; Haase, 2005; Swingler et al., 2003).  
The prevalent theory about how the reservoir is maintained  is that long-living 
cells, like central memory  CD4+ T lymphocytes, persist for the whole life of the 
patient by homeostatic proliferation induced by cytokines like IL-7 (Chomont et 
al., 2009; Dahl and Palmer, 2009; Shen and Siliciano, 2008). This theory is sup-
ported by the detection over the time of a constant level of latently infected cells 
as measured by the Infectious Units Per Millions Assay (IUPM) and by the quanti-
fication of integrated HIV DNA in patients (Chomont et al., 2009; Finzi et al., 
1997; Siliciano et al., 2003; Wong et al., 1997). 
However, it was also suggested that different mechanisms of persistence may 
occur in different subsets of latently infected cells (Chomont et al., 2009). 
ASSAYS TO MEASURE THE RESERVOIR 
The existence of a viral reservoir constitute the major barrier to viral eradication 
and thus the measure of its extent can provide an essential parameter to evalu-






The first assay established to measure the viral reservoir is the Infectious Units 
Per Millions (IUPM), also called as Viral Outgrowth Assay (VOA), developed by 
Siliciano and Wong (Finzi et al., 1997; Wong et al., 1997). This method consists of 
the serial dilution of resting CD4+ T cells isolated from patients under HAART and 
their activation by PHA in the presence of T lymphoblasts to allow the spreading 
of infection in such target cells. The count of positive wells for the spreading of 
infection allows thus to estimate the number of latently infected cells which re-
verted to productive infection: therefore the major advantage of this method is 
the detection of the portion of the viral reservoir that can be successfully in-
duced to release infectious virus. 
However, in specific groups of patients, like the Elite Suppressors (ES), the size of 
the viral reservoir is so reduced to be under the limit of detection with the IUPM 
assay: in this case the measurement of the integrated HIV DNA provides a better 
alternative to estimate the viral reservoir, even if the presence of defective inte-
grated provirus could lead to its overestimation(Brussel et al., 2005; Chun et al., 
1997). 
Recently, the group of Chomont (Procopio et al., 2015) developed a novel assay 
to measure the inducible viral reservoir. The TILDA assay ( Tat/Rev Induced Limit-
ing Dilution Assay) is based on the assumption that multiple-spliced HIV RNAs are 
usually poorly expressed within latent cells and thus its transcriptional induction 
upon cellular activation can provide the quantification of cells carrying an induc-
ible replication-competent provirus. Thus this assay provides a sensitive detec-
tion of that specific subset of cells which carry a non-defective integrated provi-
rus, since it has been observed that many defective HIV genomes have deletions 
in the Tat/Rev genes and thus their mRNA are unlikely to be detectable (Ho et al., 
2013). 
MOLECULAR MECHANISMS OF POST-INTEGRATIVE LATENCY 
Taking advantage of the previous mentioned assays and of the quantification of 
the integrated HIV DNA in CD4+ T cells, it was possible to verify that the size of 
the viral reservoir is not much affected by the administration of  the antiretrovi-
ral therapy (Chomont et al., 2009; Siliciano et al., 2003) and that each patient 
seems to maintain a stable number of latently infected cells during all the course 
of infection.  
Thus, the comprehension of the molecular details behind the establishment of 





in the acute and latent phase of infection, to achieve a “sterilizing cure” to eradi-
cate the virus.  
The establishment of latency within infected cells is a complex process depend-
ing on multiple mechanisms most of which are still a matter of debate and inves-
tigation. During pioneering studies on the topic, a bias was posed in proposing 
the transcriptional mechanisms as the predominant way to maintain the viral la-
tency. 
Nowadays increasing evidence support the idea that, even if the transcriptional 
silencing of the provirus plays a major role in this process, it could not be suffi-
cient to explain the tightly regulated phenomena of latency, and it was proposed 
the existence of different post-transcriptional mechanisms contributing to la-
tency to be investigated. 
 
TRANSCRIPTIONAL MECHANISMS IN VIRAL LATENCY 
The transcriptional silencing of the provirus is definitely the results of a number 
of events and condition occurring together within latent cells: the site of integra-
tion and the state of chromatin condensation at the viral promoter firstly con-
tribute to render the chromatin inaccessible to the transcription complex.  
Moreover, the limited action of the transcription complex, is a crucial block to vi-
ral expression and it results as a consequence of both the limited availability and 
altered activation status of the transcription factors. To impair the transcription 
al the viral promoter a big contribution is given by the modulation in the levels 
and in the activity of the viral trans-activator Tat which is absolutely required to 
enhance both the initiation of transcription and  the elongation process.  Last but 
not least, the cellular pathway of RNA interference was also shown to be in-











The analysis of the HIV provirus in both in vitro models of latency and in resting 
CD4+ T cells from HIV+ patients revealed that the preferential sites of integration 
were regions within actively transcribing genes (Han et al., 2004; Shan et al., 
2011), supporting the idea that the establishment of latency is unlikely to be re-
lated to integration of the provirus within heterochromatic region. 
Nevertheless epigenetic modifications of the chromatin at the local site of inte-
gration could influence the availability of the LTR promoter to the cellular tran-
scription factors. 
Despite the site of integration, the nucleosome Nuc-0 and Nuc-1 were found to 
bind the 5’viral LTR respectively upstream of the modulatory region and down-
stream of the viral promoter thus not only physically impeding the processivity of 
Transcriptional mechanisms  in viral latency - from Archin et al.; Nat. Rev. Microbiology 2014  
HIV-1 transcriptional silencing is maintained by several mechanisms. a) transcription factors 
are sequestered in the cytoplasm ; b) epigenetic modification at the viral promoter; c) tran-
scriptional interference by RNA PolII readthrough; d/e) inactivation of the p-TEFb complex. 







the cellular RNA polymerase, but also occupying the binding sites for the tran-
scription factors and the regulatory proteins (Verdin et al., 1993). 
A deeper analysis of the chemical modification to Nuc-1 showed markers associ-
ated with condensed and silent chromatin, such as the methylation of the his-
tone3 and the lack of proper acetylation (Pearson et al., 2008; Van Lint et al., 
1996): such epigenetic modifications are due to the recruitment at the viral pro-
moter of the Histone Methyl-Transferase (HMT) and the Histone Deacetylases 
(HDAC) by several cellular factors like Sp1, CBF-1 and CTIP2 (Jiang et al., 2007; 
Marban et al., 2007; Tyagi and Karn, 2007). 
The epigenetic modification operated by HMTs and HDACs are important not 
only to affect the nucleosome assembly. The acetylation of non-histonic sub-
strates is important to regulate the activity of some transcription factors, such as 
RelA, or cellular factors such as HIC1. HIC1 is a repressor of transcription pro-
posed to be involved in the establishment of latency within microglial cells, the 
major viral reservoir within the central nervous system, along with CTIP2 and 
HMGA1; it was shown that its acetylation status, regulated by SIRT1, influences 
its binding to the viral Tat, thus affecting the Tat-mediated regulation of viral 
transcription (Le Douce et al., 2016). The activity of Tat in microglial cells was 
also found to be negatively regulated by CTIP-2 which redirected Tat localization 
to inactive region of the chromatin (Rohr et al., 2003). 
The catalytic activity of HMT is exerted not only on histones but also directly on 
the CpG islands at the viral 5’LTR, even if it is still unclear whether the methyla-
tion status of the DNA represent an important contribution to latency (Blazkova 
et al., 2012). 
The viral LTR contains multiple binding sites to different cellular transcription fac-
tors like NF-kB, NFAT, SP1 and the activator protein AP1: the activation status 
and the availability of such factors appears to be one of the major contributors 
to the transcriptional block in latency. 
The inhibitory homodimeric form of NF-kB, p50/p50, binds the viral LTR to re-
press transcription, while the active heterodimeric form p50/RelA is sequestered 
in the cytoplasm by the IkB-α inhibitor; the stimulation of the PKC pathway 
would result in the release of the active p50/RelA form which leads to the dis-
placement of the p50/p50 complex from the LTR and to the recruitment of HATs 






Once the transcription starts, the RNA Pol II get stalled and needs to be phos-
phorylated to proceed with the elongation of the transcripts: thus the recruit-
ment of the Positive Transcription Elongation Factor b complex (P-TEFb) is the 
crucial event to avoid the premature termination of transcritpion. 
The P-TEFb complex contains the Cyclin T1 and the cyclin-dependent kinase 9 
(CDK9): both of this factors are reported to be expressed at limiting levels in rest-
ing CD4+ T cells (Budhiraja et al., 2013). Besides the limited availability of these 
factors in resting conditions, the P-TEFb complex is sequestered in a large re-
pressed ribonucleoprotein complex containing the 7SK RNA and the proteins 
HEXIM2, MePCE and LARP7 (Michels et al., 2004): release of the active P-TEFb 
complex is essential to induce the proper phosphorylation of RNA Pol II by CDK9 
and thus to overcome the initial block of the transcriptional machinery (Fujinaga 
et al., 2004; Ping and Rana, 1999). 
POST-TRANSCRIPTIONAL MECHANISMS IN VIRAL LATENCY 
The transcriptional silencing of the integrated provirus plays a major role in the 
maintenance of HIV latency and the removal of these transcriptional blocks is 
without a doubt fundamental to achieve viral reactivation. 
Nevertheless, it was demonstrated  that when latently infected cells from HIV+ 
patients are stimulated with transcriptional inducers to restore viral gene ex-
pression, the rescue of full viral particles from these cells was affected, even if a 
proper level of intracellular viral transcripts was detected (Mohammadi et al., 
2014). 
This observation demonstrate that overcoming transcriptional limitation is nec-
essary but not sufficient to revert latency: several post-transcriptional blocks ex-
ist within latent cells and impede full viral reactivation even upon proper viral 
transcription. Limiting levels of the host factors involved in mRNA metabolism 
can affect proper stabilization, splicing and export of the viral mRNAs; moreover 
the activity of those factors could be altered in resting lymphocytes (Sarracino 
and Marcello, 2017). 
Taking advantage of ultra sensitive methods for intracellular and extracellular vi-
ral RNA detection, it was possible to determine that in resting CD4+ T cells from 
HIV+ patients under HAART, both unspliced and multipli-spliced viral mRNA were 
present (Lassen et al., 2004). An accurate analysis of the subcellular localization 





existence of a block in the nuclear export of viral RNAs. Notably, upon cellular ac-
tivation by TCR stimulation, both US and MS mRNAs exhibited a proper cyto-
plasmatic distribution within 72 hours (Lassen et al., 2006).  
More evidences on the existence of post-transcriptional mechanisms to viral si-
lencing came from the use of in vitro model to reproduce the cellular environ-
ment of viral latency. 
In an in vitro model of latency based on the direct infection of resting PBLs, 
abundant levels of unspliced viral transcripts were detected, while the spliced 
forms were less represented demonstrating an inefficient splicing process in such 
conditions (Pace et al., 2012). The concomitant analysis of intracellular viral pro-
teins revealed that the level of Gag was much lower than expected based on its 
high mRNA concentration suggesting an additional block in the nuclear export of 
the unspliced mRNAs. 
These observations suggested that, in latently infected cells, both viral mRNA 
biogenesis and their nuclear export are affected thus leading to defects in viral 
protein production. 
In accordance with the hypothesis that defective mRNA processing could con-
tribute to post-integrative latency, it was reported that several factors involved 
in mRNA metabolism are limiting in CD4+ T cells under resting conditions and 
that their expression is increased only upon cellular activation (Mohammadi et 
al., 2014); some of these factors were previously found to interact with the viral 
RNA and in some cases it was shown that their overexpression can revert latency 
both in cellular models and in primary lymphocytes from patients. 
The Polypyrimidine Tract Binding Protein (PTB) is a  cellular factor involved in the 
post-transcriptional regulation of gene expression by different processes, like 
mRNA splicing (Kosinski et al., 2003; Singh et al., 2004); PTB was found to associ-
ate with the viral mRNA (Black et al., 1996) and to be barely expressed in cells of 
the viral reservoir. Notably it was demonstrated that PTB overexpression in rest-
ing latently infected CD4+ T cells was able to restore full virus production (Lassen 
et al., 2006). 
The PTB-associated Splicing Factor (PSF) plays several roles in cellular mRNA me-
tabolism (Emili et al., 2002; Shav-Tal and Zipori, 2002) and  was proposed to en-
hance viral RNA stability by preventing their degradation (Kula et al., 2013b), a 





cytes, the activity of PSF and hnRNP A1 is finely regulated by phosphorilation via 
the MAP-kinase signal-integrating kinases (Mnks). The phosporylation of PSF oc-
curs differently in resting and activated CD4+ T cells and this influence the inter-
action of PSF with other host factors leading to a modulation in its activity (Bux-
adé et al., 2008) 
In particular, in resting lymphocytes, the protein kinase GSK3 phosphorylates PSF 
which, in turn, strongly associates with TRAP150 and BTF, two host factors impli-
cated in mRNA processing, stability and, along with hnRNP A1, in splicing regula-
tion. It was demonstrated that TRAP150 binds PSF on its RNA-recognition motifs 
(RRM), an interaction which abrogate PSF binding to target mRNAs (Heyd and 
Lynch, 2010; Yarosh et al., 2015). 
PSF was found to be a part of the Rev-RNA ribonucleoproteic complex along with 
the nuclear matrix protein MATR3, a factor linked to the Rev-mediated export 
(Kula et al., 2011b). Both MATR3 and PSF were found to be limiting under resting 
conditions and to be promptly upregulated upon cellular activation suggesting 






































The involvement of miRNA-mediated silencing in the process of latency was 
demonstrated by showing the physical association between Ago2 and HIV 
mRNAs and their co-localization within P-bodies (Chable-Bessia et al., 2009). Re-
markably silencing of several RNAi effectors such as DGCR8 or Drosha, lead to 
reactivation of latent provirus from PBMC of HIV+ patients under cART. More-
Post-Transcriptional blocks to latency reversal – modified from Sarracino and Marcello, Curr. 
Pharm. Des. 2017  
HIV-1 transcriptional silencing is maintained by different mechanisms.  
1) epigenetic and molecular blocks inhibit HIV-1 expression; transcriptional activation is ob-
tained by LRAs; 
2) efficient splicing and export of fully-spliced transcripts is require to allow the production of 
regulatory proteins; 
3) limiting levels of cellular Rev co-factors results in nuclear retention of viral intron-containing 
mRNAs; 
4) translation of properly chemically modified viral transcripts is inhibited in latent cells by sev-







over, the 3’UTR of HIV mRNAs contains several putative binding sites for cellular 
miRNAs such as miR-125b, miR-150, miR-223, miR-382 and miR-28 (Huang et al., 
2007); all of them were found to be more abundant in resting than in activated 
CD4+ T cells and to specifically restrict viral replication. 
TOWARD A STRATEGY TO CLEAR THE VIRAL RESERVOIR 
Since it was observed that long-lasting  treatment with the antiretroviral drugs 
was not sufficient to eradicate the virus, a first attempt to clear the viral reser-
voir was done with intensified drug regimens; unfortunately it was found that 
the use of higher drug dosage didn’t affect the size of the reservoir (Gandhi et al., 
2010). 
Currently, different strategies have been suggested to specifically target  the viral 
reservoir. 
Among them, the “shock and kill” therapy proposes that, the reactivation of the 
silent provirus from  latently infected cells, could be achieved by pharmacological 
treatment with transcriptional inducers collectively named as Latency Reversal 
Agents (LRAs). Viral reactivation will consequently lead to the clearance of the 
infected cells by cytotoxic T lymphocytes whose activity could be also stimulated 














To this task, a panel of drugs has been tested alone or in combination to restore 
proper viral transcription: chromatin remodelling agents, NF-kB inducers and P-
TEFb stimulators are the best characterized compounds. 
Among chromatin remodelling agents, we find inhibitors of the histone deacety-
lase (HDACi) and inhibitors of the DNA methyltransferase (DNMTi); the latter 
ones are less exploited since the role of DNA methylation in the establishment of 
latency is still controversial (Blazkova et al., 2012), even if some studies (Bern-
hard et al., 2011; Bouchat et al., 2012; Imai et al., 2010)  showed that inhibitors 
of the methylases G9a and SUV39H1 can revert HIV latency by inhibiting the me-
thylation of Nuc-1. 
The panel of HDACi is an heterogeneus group of drugs including both natural and 
synthetic compounds which showed different specificity for the different classes 
of HDACs: this group of drugs is well characterized thanks to their use in clinic for 
Use of LRAs to achieve a sterilizing cure – from Durand, Blankson and Siliciano; Trends Immunol. 
2012 
Patients on a three-drug HAART therapy regimen (yellow, blue and green boxes) have unde-
tectable levels of  viremia, even if occasional “blips” can occur. Ideally, the administration of 









their anti-cancer properties and for the treatment of neurodegenerative disor-
ders. 
Among the most potent HDACi there are Valproic Acid (VPA), suberoylanilide hy-
droxamic acid (SAHA), Romidepsin and Panabinostat; their effect is not limited to 
histones but also non-histonic proteins can represent a substrate for their activ-
ity.  In the case of the NF-kB subunit p65, the deacetylation by HDAC3 induces its 
binding to the IkB-α inhibitor thus leading to its sequestration into an inactive 
complex which results in transcriptional silencing; the restoration of proper ace-
tylation on p65 leads its release from the inhibitory complex to allow the forma-
tion of the active NF-kB heterodimer and the iniziation of transcription. 
Thanks to its broad spectra of actions directed to different events in the tran-
scriptional process, the group of HDACi constitute a powerful class of drugs for 
latency reversal. The potency of HDACi to viral reactivation have been widely 
tested in several latency models and in resting CD4+ T cells from HIV+ patients 
(Quivy et al., 2002; Reuse et al., 2009; Søgaard et al., 2015); unfortunately the re-
sults are frequently controversial since it was not possible to achieve a complete 
latency reversal in all the condition tested.  
The activation of transcription factors NF-kB and AP-1 is achieved by stimulation 
of the protein kinase C (PKC) pathway and thus PKC agonists, such as prostratin 
and bryostatin-1, have been tested alone or in combination with HDACi as la-
tency reversal agents in different model of latency (Mehla et al., 2010; Pérez et 
al., 2010; Reuse et al., 2009). 
To enhance the activity of the elongation factor P-TEFb  different approaches 
have been proposed. The stimulation of the P13/Akt pathway induces the re-
lease of P-TEFb from the inhibitory complex formed with HEXIM and the 7 SK 
RNA while the inhibition of the bromodomain protein 4 (BRD4), which bind di-
rectly to P-TEFb on the same binding site of Tat, would allow the rescue of 
proper Tat activity on the enhancement of transcripts elongation.  
The hexamethylene bisacetammide (HMBA) is an activator of P13/Akt pathway 
and was tested both in latency models and in CD4+ T cells from HIV+ patients for 
its ability to revert latency; unfortunately all those tests gave disappointing re-
sults (Choudhary et al., 2008; Yang et al., 2009). 
JQ1 is a small molecule which acts as a selective inhibitor of BRD4; it was tested 





developed by the group of Siliciano, JQ1 proved to be effective but these result 
was not confirmed in other cellular models (Boehm et al., 2013). 
Despite the promising approach of the “shock and kill” strategy to target the viral 
reservoir by acting on proviral transcription, the results accumulated during the 
past years of experimentation are disappointing. 
The restoration of viral transcription seems to be not sufficient to revert the la-
tent state suggesting that several steps of the viral replication are not success-
fully induced by the currently available LRAs thus leading to the failure of these 
treatments. The development of drugs to overcome the post-transcriptional 
blocks to latency reversal would provide a powerful tool which, used in combina-
tion to the well-known LRAs, could provided a more incisive strategy to target 
the viral reservoir. 
CURRENT MODELS FOR THE STUDY OF LATENCY 
Investigation on the molecular mechanisms behind viral silencing and the neces-
sity to test therapeutic strategies to target the viral reservoir, require a proper in 
vitro model of latency; the small number of latently infected cells in patients and 
their lack of a proper distinguishable markers makes the attempt to derive such 
cells directly from patients almost not feasible. 
Moreover the use of immortalized cell lines, even if useful and practical, pone 
several issuses such as the clonal nature of the integration site, the altered cellu-
lar environment related to the immortalizing mutations and the cycling nature 
due to an imbalanced growth control. 
The development of in vitro models of latency based on primary cells appear to 
be the best way to study the characteristics of the viral reservoir in a more 
physiological environment and different laboratories have explored the possibil-
ity to reproduce latent infection by taking advantage of different techniques. 
The model developed in Lewin’s laboratory (Cameron et al., 2010; Saleh et al., 
2007) exploits the use of several chemokines to induce rearrangement in the cy-
toskeleton of resting CD4+ cells without causing activation: such structural 
changes allow the establishment of proper infection with a wild-type NL-4.3 HIV 
strain. 
The model proposed by Siliciano (Yang et al., 2009) is articulated in two different 





stimulated and transduced to express Bcl-2 to overcome apoptosis. After a brief 
culture in IL-2 these active cells are infected with a replication-defective NL 4.3 
GFP reporter virus and left in culture for at least 3 weeks to allow the establish-
ment of latency: the cytofluorimeter is then used to sort only the GFP-negative 
cells showing a resting memory phenotype. 
The Spina model (Spina et al., 1995, 1997) is based on the observations that la-
tent infection can be established in resting CD4+ T cells upon exposure of a 
mixed population of primary CD4+ T lymphocytes, including both dividing and 
quiescent cells, to wild type HIV. Basically co-colture of dividing infected cells is 
used to obtain latent infection in non-replicating bystander lymphocytes. 
Direct infection of resting primary CD4+ T cells is exploited also in the model that 
the Greene’s group (Lassen et al., 2012) derived from the modification of 
O’Doherty model (Swiggard et al., 2005); infection of quiescent cells is achieved 
by increasing the efficiency of virus delivery (a replication competent NL 4.3 con-
taining luciferase reporter gene in place of Nef) by the use of spinoculation. 
Taking account of the different subsets of cellular populations exploited and the 
variety of techniques and cytokines or chemokines implied in the presented sys-
tems, it seems to be unlikely to obtain a uniform result from experiments per-
formed in these different models. 
  




AIM OF THE THESIS 
The identification of MATR3 as a component of the Rev-RNA nuclear complex 
prompted an investigation of its role in the course of HIV-1 infection. My thesis 
work is therefore finalized to assess the functional role of MATR3 during viral 
replication, both during the acute infection and upon establishment of the latent 
phase. To this aim, I investigated the effect of MATR3 modulation in Jurkat cells 
and primary PBLs in the context of infection with a replication-competent HIV-1. 
I either depleted or overexpressed MATR3 within HIV-infected lymphocytes and 
assessed the impact on viral replication in terms of viral mRNA metablosm, viral 
protein production and full virion release.  
To study the putative role of MATR3 in the establishment of HIV-1 latency I used 
the J-Lat cell model. I evaluated the effect of MATR3 depletion on latency 
reversal when the transcription of the silent provirus is restored by TNFα 
stimulation: I analysed both the effect on transcriptional reactivation and full 
viral particle rescue from latent cells. 
To better characterize the actual cellular context of latency I used primary PBLs 
from healthy donors and from HIV-infected patients and analysed the levels of 
MATR3 during treatment with clinically-tested Latency Reversal Agents. 
Finally I tried to establish a proper model of viral latency, based on either 
primary or immortalized lymphocytes,  to test the effect that MATR3 
overexpression exert on latency reversal when is combined to treatment with 
Latency Reversal Agents. 
In conclusion I found that MATR3 is a positive regulator of HIV-1 replication 
during acute infection in Jurkat cells and primary PBLs: I could assess that MATR3 
acts as a Rev co-factor to enhance the export of intron-containing viral 
transcripts and I could exclude its involvement in the process of viral 
transcription. 
I assessed that MATR3 depletion affects latency reversal in J-Lat cells in a post-
transcriptional way and that MATR3 levels are limiting in primary resting PBLs 
from healthy donors and HIV-1 infected patients. Moreover I confirmed that the 
low basal expression of MATR3 is not induced by treatment with LRAs while 
cellular activation by PHA or TCR stimulation promptly increase MATR3 levels. 
These last observations suggest that MATR3 could be one of the limiting factors 




to latency reversal and that its inadequate expression within cells of the viral 
reservoir could affect their capacity to restore full viral particles production upon 
treatment with LRAs. 
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MATR3 depletion affects acute HIV-1 viral replication in human lymphocytes 
The Rev-mediated nuclear export of viral intron-cointaining  mRNAs  requires the 
concerted action of several host-factors exploited by the virus to assure the effi-
cient completion of its replication cycle. The cellular component of the nuclear 
matrix MATR3 was previously identified in our laboratory to be involved in this 
process and to specifically interact with Rev. 
When I joined the laboratory of Molecular Virology the post-doc Lavina Gharu 
was working on this project and thus the initial stages of my work are closely re-
lated to hers: figure 1, 2 and 3 are essentially her contribution and I worked 
along with her to repeat some of those data. 
To better investigate the role of MATR3 in the context of HIV-1 infection we 
screened 5 different shRNA targeting MATR3 mRNA (either in the ORF or in the 
3’UTR)  to stably deplete this factor from target cells, either immortalized or pri-
mary  T-cell lines. 
Each shRNA was expressed from a lentiviral vector pseudotyped with the VSV- 
envelope protein (VSV-G) as described in Materials and Methods; a non-
targeting scramble shRNA was chosen as a control (shCTRL). 
 Jurkat cells were transduced and kept under puromicin selection for 3-4 days; 
cells were then lysed in Laemmli Buffer and the level of MATR3 was analyse by 
immunoblot. 
Two shRNA (sh905 and sh906) showed the strongest efficacy in inducing an effi-
cient depletion of MATR3 (Figure 1A). 
In order to assess the persistence of the depletion in Jurkat cells the levels of 
MATR3 were measured at different time points following selection. As shown in 
Figure 1B, specific and long-lasting suppression of MATR3 could be observed up 
to two weeks : sh905 and sh906 were thus selected for the subsequent studies 
throughout this work. To exclude any cytoxic effect related to MATR3 depletion 
we checked cell viability of Jurkat cells transduced with sh905, sh906 and shCTRL 
lentivectors by tripan blue exclusion test: we could thus assess that MATR3 de-














To investigate the role of MATR3 in the context of acute HIV-1 infection, Jurkat 
cells were transduced with the above mentioned sh905 , sh906 or shCTRL lenti-
viruses and kept under puromicin selection for 4 days. MATR3 depleted Jurkat 
cells were then infected with the full-lenght HIV-1 NL4.3 and the overall effect on 
viral replication was assessed by  viral particle quantification in the culture media 
through p24 ELISA. 
Fig.1- screening of shRNA targeting MATR3 
A) HeLa cells were transduced with different lentivectors targeting MATR3 (shMATR) or 
with a control (shCTRL); 4 days after puromicin selection cells were harvested and analysed 
by immunoblot. Tubulin is the loading control. B) Jurkat cells were transduced with len-
tivectors targeting MATR3 (sh905; sh906) or with a control (shCTRL); MATR3 depletion was 
monitored for two weeks (B). Actin is the loading control. C) The Tripan Blue exclusion test 






MATR3 depleted cells exhibited a strong impairment in viral replication since no 
increase in extracellular viral particle was observed up to 14 days post infection 
(Figure 2A). 
 To confirm the essential role of MATR3 in HIV-1 replication in a more physiologi-
cal cellular model we recapitulated this experiment in primary PBLs. Again upon 
MATR3 depletion a striking impairment in HIV-1 replication was observed for 
both sh905 and sh906 compared to shCTRL as shown in Figure 2B. 
These data confirm the role of MATR3 as a positive regulator of HIV-1 replication 
during acute infection.  







Fig.2-MATR3 depletion affects viral repliaction in Jurkat cells and in PHA-activated primary 
PBLs.  
A) MATR3 depleted Jurkat cells were infected  with the full lenght HIV-1 NL4.3. Viral replica-
tion was monitored for two weeks  by p24 ELISA on culture supernatants. 
B) PBLs isolated from healthy donors were activated with PHA for 72 hours and transduced  
with lentivectors to deplete MATR3. MATR3 depleted PBLs were infected with the replication 







MATR3 acts post-transcriptionally 
Previous work in our laboratory identified MATR3 as a co-factor in Rev-mediated 
nuclear export of intron-containing HIV-1 RNAs. In order to confirm if this was 
the case also in acute HIV-1 infection  we infected MATR3- depleted Jurkat cells 
with a VSV-G pseudotyped HIV-1 vector NL4.3-R-E-luc containing the firefly 
luciferase reporter gene within the Nef region which is expressed  as the product 
of a fully spliced transcript. 
Since we could not observe differences in luciferase expression upon MATR3 de-
pletion we could exclude a direct role of MATR3 in viral transcription (Figure 3A); 
moreover the lack of effect on luciferase expression also indicate that MATR3 
depletion was not affecting the metabolism of fully spliced viral mRNAs. 
To investigate a possible effect of MATR3 depletion on the nuclear export of in-
tron-containing viral mRNAs nuclear and cytoplasmic fraction of infected cells 
were separated (Figure 3D) to quantify the relative amount of US-mRNAs by 
qPCR in the two compartment. 
The amount of US transcripts was significantly reduced within the cytoplasm and 
slightly increased in the nucleus (Figure 3B):  a trend compatible with a defective 
export of this specific class of mRNAs was also confirmed by the immunoblot for 
the intracellular viral Gag protein, fully dependant on the export of unspliced vi-
ral mRNAs, which was reduced upon MATR3 depletion (Figure 3C). 
These experiments confirmed that MATR3 regulates nuclear export and expres-





                      
 
                         Fig 3- MATR3 acts post-transcriptionally. MATR3 depleted Jurkat cells were  infected 
with the viral vector pNL-4.3-R-E-luc; luciferase expression was measured 48hours 
post infection and normalized to total protein level measured by Bradford Assay (A). 
Results  from three indipendent experiments are shown as mean values + SD. 
Unspliced RNA levels were quantified by real time PCR in the nuclear and cytoplasmic 
fraction of MATR3 depleted Jurkat cells (B). Purity of nucleo-cytoplasmic fraction (D) is 
assessd by immunoblot for the cytoplasmic marker Hsp90 and the nuclear marker 
PARP. As expected MATR3 is detected only in the nuclear fraction of CTRL Jurkat cells. 
RNA levels are normalized to GAPDH. Results  from three indipendent experiments are 
shown as mean values + SD.  MATR3 depleted Jurkat cells were infected with the rep-
lication competent HIV-1 NL4.3 and 48 hours post- infection cells were harvested and 







MATR3 overexpression enhances HIV-1 replication in human lymphocytes 
Next we wished to investigate the effect of overexpressing MATR3 in acute HIV-1 
infection. To this end a flag-tagged version of MATR3 was cloned into the 
pWPI_BLR lentiviral vector as described in materials and methods. 
Transduction of Jurkat cells with the lentiviral vector to express the flag-MATR3  
(fMATR) resulted in higher MATR3 RNA and protein levels (Figure 4A; 4B) com-
pare to cells transduced with a control lentiviral vector (CTRL). 










FIG.4- Efficient MATR3 overexpression in Jurkat cells.  Transduction of Jurkat cells with a lentivec-
tor to deliver a flag-tagged MATR3 (fMATR) resulted in higher MATR3 mRNA (A) and protein levels 
(B) compared to cells trated with the control vector (CTRL). RNA levels were normalized to GAPDH; 
B-actin is the loading control in the immunoblot. Results from two indipendent experiments ex-






Infection of these cells with HIV-1 NL4.3 resulted in increased intracellular Gag 
(Figure 5A); nucleo-cytoplasmic fractionation of infected Jurkat cells overexpress-
ing MATR3 revealed a major  decrease of US-HIV RNA in the nucleus while MS 
HIV RNA were not affected (Figure 5B; 5C). Decrease of US RNA in the nucleus is 
compatible with an enhanced export of these transcripts mediated by MATR3 
through the Rev pathway while the steady-state invariant US RNA level in the cy-
toplasm could be explained by the increased production of viral particle (Figure 
5A).  
However we couldn’t exclude a MATR3-dependent effect on stability of HIV RNA 
mediated by the zinc-finger antiviral protein (ZAP)- complex as proposed by 









To finally confirm that  MATR3 is a positive regulator of HIV-1 replication primary 
PBMCs activated for 4 days with PHA/IL2  were transduced to overexpress 
FIG.5- MATR3 overexpression enhances the export of US mRNAs.  Jurkat cells overexpressing 
MATR were infected with the replication competent HIV-1 NL 4.3; 48 hours post infection the 
cells were harvested and subjected to nuclear-cytoplasmic fractionation. MATR3 overexpres-
sion  (fMATR) resulted in increased intracellular Gag levels; B-actin is the loading control (A). 
Quantitave analysis of viral US (B) and MS (C) mRNAs in nuclear and cytoplasmic fraction was 
performed by real time PCR; RNA levels are normalized to GAPDH. Results from two indipen-






MATR3 and than infected with HIV-1 NL4.3.Viral production was monitored in 
the culture media with a p24 ELISA and showed that increased levels of MATR3 
resulted in higher amount of viral particles in the supernatant (Figure 6). 
                                       
 
These data complement the depletion data described above and confirm the role 
of MATR3 as a post-transcriptional regulator of HIV-1 RNA export and ultimately 
viral replication.  
However, a major hurdle to HIV-1 eradication is the persistence of viral reservoir 
that carry a silent, but transcriptionally competent, integrated copy of the viral 
genome. 
Since few study have explored post-transcriptional blocks to HIV-1 reactivation 
we addressed this topic further. 
 
FIG.6- MATR3 overexpression enhances viral replication in primary PBLs  
PHA-activated primary PBLs were transduced with a lentivector to overexpress MATR3 and 
infected with the replication competent HIV-1 NL 4.3.Viral replication was monitored  by p24 







MATR3 depletion affects latency reversal in J-lat cells 
To address the question if MATR3 can play any role in the reactivation of HIV-1 
latency we took advantage of a well known model for the study of latency, J-lat 
cells, which contain an integrated but silent provirus encoding for GFP as a re-
porter gene for viral transcription, expressed from an HIV MS mRNA. 
Cells were transduced with shMATR3 lentiviral vectors to deplete MATR3 (Figure 
7A) and then stimulated with TNFα to induce HIV transcription from the latent 
provirus. As shown in Figure 7B, cell-associated Gag protein levels were markedly 
reduced upon MATR3 depletion with sh905 and sh906. Consistently, p24 levels in 
the medium were also reduced (Figure 7C), while HIV-1 transcription was not af-
fected by MATR3 depletion (Figure 7D). 
These experiments show that MATR3 removal results in a reduced ability of 
TNFα to reactivate HIV-1 from latency. One intriguing hypothesis is that certain 
host factors, which are essential for HIV-1 gene expression, might be limiting 














FIG.7- MATR3 depletion affects  the post-transcriptional steps of viral reactivation in J-lat 
cells  
J-lat 8.4 cells were transduced  with a lentivector to knockdown MATR3 ( shMATR) leading 
to an efficient and  stable MATR3 depletion (A). MATR3 depleted J-Lat 8.4 were stimulated 
with TNFα  for 48 hours and viral reactivation was assessed in terms of intracellular Gag (B), 
viral particle in the supernatant  by p24 ELISA (C) and GFP expression  by FACS analysis (D). 
B-actin is the loading control in the immunoblots. Results from three indipendent experi-






MATR3 is limiting in primary resting PBMCs  
To better characterize the cellular context of the viral reservoir we analysed the 
expression levels of several host factors in quiescent primary PBMCs and PBLs. 
Primary PBMCs and PBLs purified from healthy donors were cultured in IL2 alone 
or activated with PHA for different time points (24, 48, 72 hrs or 6 days) and their 
protein extract was analysed with an immunoblot. We checked for factors in-
volved in mRNA synthesis and metabolism at different stages, from transcription 
(Cyclin T1) to RNA stabilization and export (MATR3, PSF, PTB). 
We observed that these factors were barely expressed in quiescent PBLs and 
readily induced by PHA activation (Figure 8A). The same was observed for puri-
fied primary CD4+ T cells (Figure 8B) that represents the best-characterized res-
ervoir of latent HIV-1. 
Hence, levels of MATR3 and other post-transcriptional factors required for full 
reactivation of HIV-1 are low in quiescent lymphocytes, possibly contributing to 
HIV-1 latency.  
          
                   
 
FIG.8- Expression of MATR3 in  primary  lymphocytes  
Primary PBMC, PBLs (A) and CD4+T cells (B) were isolated from healthy donors as described 
in Materials and Methods.The levels of transcriptional and post-transcriptional factrors 
(MATR3, PSF, CyclinT1, PTB) were analysed by immunoblot prior and post-PHA activa-






MATR3 is not modulated by LRAs 
We focused our analysis on the cellular context of resting primary PBMCs which 
are the cell types mainly composing the viral reservoir:  we sought to investigate 
deeper the actual behaviour of MATR3 and its modulation upon pharmacological 
treatments with the newly proposed latency reversing agents (LRAs). 
To this aim we selected several drugs from the panel of LRAs and tested the ef-
fect  these drugs exert on endogenous MATR3 levels within primary resting 
PBMCs. 
The drugs selected for the screening  are transcriptional inducer acting through 
different mechanism and in particular we choose the PTEN inhibitor Disulfiramin, 
the two histone deacetilase inhibitor SAHA and Romidepsin and the BET-inhibitor 
JQ1 in combination to the PKC agonist Ingenol B; we used PHA as a positive con-
trol for cellular activation. 
Romidepsin is a relatively newly discovered HDAC inhibitor whose potent action 
in latency reversal is  arousing increasing interest (Søgaard et al., 2015) while 
SAHA has a well-established use in clinic. SAHA was approved in 2006 for the 
treatment of cutaneous T cell lymphoma (CTCL) and is currently tested in several 
clinical trials for other types of cancer.  Moreover, in preclinical investigation, 
SAHA demonstrated to be a powerful activator of latent HIV-1 transcription in 
different cellular model of latency (Archin et al., 2009). 
The combination of JQ1 and Ingenol B is an intriguing approach which associate 
the nuclear translocation of NF-kB  through the PKC pathway induced by Ingenol 
B to the release of P-TEFb induced by JQ1 (Darcis et al., 2015). 
To set the appropriate concentration to use for each drug we refer to the plasma 
concentration (when available), the tolerated doses and the peak of efficacy as 
reported from literature. 









PBMCs isolated from healthy donors were cultured in IL2 alone or stimulated 
with one or a combination of drugs for 3 and 6 days; MATR3 levels were then 
analysed at the protein level by immunoblotting. 
The relative amount of MATR3 after each treatment is shown as fold change to 
unstimulated PBMCs and represent the average obtained from three healthy do-










FIG.9- MATR3 is not modulated upon treatment with LRAs in PBLs from healthy donors  
Primary PBLs were isolated from healthy donors as described in Materials and Methods and 
stimulated with different LRAs or PHA-activated; after 3 (A) and 6 days (B) of treatment cells 
were harvested and MATR3 levels analysed by immunoblot. Vimentin is the loading control. 
Western Blot quantifications of MATR3 relative levels are normalized to Vimentin by ImageJ 
and are obtained from immunoblot analysis on 3 different donors; MATR3 protein level is ex-






None of the tested drug was able to induce MATR3 protein level either after 3 or 
6 days of treatment, while PHA consistently increased MATR3 protein levels. 
Among the tested drugs we focused our attention on SAHA because of its well-
established use in clinic: we added an extra donor to the measurement and we 
confirmed again that MATR3 protein level remained low and not induced after 3 
and 6 days of SAHA treatment in resting PBMCs from healthy donors (Figure 10). 
 






To exclude a possible fluctuation of MATR3 protein levels during SAHA treatment 
at shorter time points we evaluated  the effect of SAHA stimulation at 18 and 24 
FIG.10- MATR3 is not modulated upon treatment with SAHA in PBLs from healthy donors  
Primary PBLs isolated from healthy donors were stimulated with 0,5uM of SAHA or PHA-
activated for 3 (A) and 6 days (B); the cells were then harvested and MATR3 levels analysed 
by immunoblot.Vimentin is the loading control. Western Blot quantification are obtained 
from immunoblot analysis on 4 different donors; MATR3 relative levels are normalized to 






hrs. As shown in Figure 11, no modulation of MATR3 occurs upon stimulation 
with SAHA. 
 
                                              
 
 
SAHA treatment is not sufficient to rescue full viral particles from latent cells 
obtained from HIV+ patients under cART  
 
 
FIG.11- MATR3 is not modulated upon  short treatment with SAHA  in PBLs from healthy do-
nors  
Primary PBLs isolated from healthy donors were stimulated with 0,5uM of SAHA or PHA-
activated for 18 and 24 hours; the cells were then harvested and MATR3 levels analysed by 
immunoblot. Actin is the loading control. Western Blot quantification are obtained from im-
munoblot analysis on 2 different donors; MATR3 relative levels are normalized to MOCK and 






The inability of LRAs to increase MATR3 levels within resting PBMCs from healthy 
donors lead us to extend the observation to the actual context of viral reservoirs 
ex-vivo by testing the same drugs in PBMCs isolated from aviremic HIV+ patients  
under cART. 
The experiments on samples from HIV+ patients were done in collaboration with 
Dr.Ania Kula and Dr.Carine Van Lint at the University of Bruxelles (ULB) because 
they have access to a well established cohort of HIV+ patients from the St-Pierre 
Hospital; qPCR data analysis were performed in collaboration with Alexander 
Pasternak at University of Amsterdam (AMC). 
PBMCs isolated from 3 HIV+ patients were treated for 3 and 6 days with disul-
firamin, SAHA, romidepsin or Ingenol B + JQ1 while anti-CD3/CD28 antibodies 
were used as a positive control for cellular activation; the induction of MATR3 
was measured at the RNA level by qPCR. 
The results obtained in cells from HIV+ patients recapitulate the same scenario 
observed from healthy donors in which none of the tested drugs was increasing 
MATR3 levels after both 3 and 6 days of treatment (Figure 12A). We focused our 



















Along with the effect exerted on MATR3 level we also checked for the efficiency 
of SAHA in latency reversal within the same samples: both cellular-associated 
and extracellular viral RNAs were quantified by qPCR. The measurement of intra-
cellular MS viral transcripts indicate the ability of SAHA to reactivate the tran-
scription from the silent provirus while the presence of extracellular viral RNAs 
would indicate a complete rescue of full viral particles. 
As shown in Figure 13A, cell-associated viral RNAs increased after 6 days of SAHA 
treatment at levels comparable to the one obtained with the positive control in-
dicating that SAHA is a strong inducer of transcription at the LTR site. However 
removal of transcriptional blocks after SAHA treatment is not followed by full vi-
ral particle rescue (Figure 13B) which suggest the presence of additional blocks in 
FIG.12- MATR3 is not modulated upon treatment with LRAs in PBLs from HIV-infected pa-
tients  
Primary PBLs were isolated from  aviremic HIV+ patients  as described in Materials and Me-
thods and stimulated with different LRAs  (A), with SAHA (B) or CD3/CD28-activated for 3 and 6 
days; MATR3 RNA levels  were analysed by quantitative real timePCR and normalized to total 
cellular RNA. MATR3 levels are normalized to MOCK; the number of patients included in the 
analysis is 3 for all the LRAs (A) and 7 for SAHA (B).  
A) Data sets were analysed using the Student’s t-test with significance at p<0.05. SAHA3 vs 
mock3 p=0.1917; Disulfiram3 vs mock3 p=0.351; Romidepsin3 vs mock3 p=0.1909; IngB+JQ1-3 
vs mock3 p=0.8525; CD3+CD28-3 vs mock3 0.3819; SAHA6 vs mock6 p=0.6606; Disulfiram6 vs 
mock6 p=5874; Romidepsin6 vs mock6 p=0.2681; IngB+JQ1-6 vs mock6 p=0.7147 ; CD3+CD28-6 
vs mock6 p=0.0237. 
B) Data sets were analyzed using a paired, nonparametric Wilcoxon test. p<0.05 was conside-
red statistically significant. SAHA3 vs mock3 p=0.2969; CD3+CD28-3 vs mock3 p=0.0313; SAHA6 







one or more post-transcriptional steps which impede the completion of the viral 
life cycle. 
These observation reveal that transcriptional activation is necessary but not suf-
ficient to revert latency from cells within the viral reservoir. Since MATR3 have 
been found to be limiting during SAHA treatment we hypothesized a role for fac-













FIG.13- Treatment with SAHA efficinetly induces HIV-1 transcription  
A) Cell-associated unspliced HIV-1 RNA (CA-US HIV-1 RNA) extracted from ex vivo cultures of 
CD8-depleted PBLs from 7 aviremic HIV+ patients  was quantified by RT-qPCR and expressed 
as HIV RNA copy numbers/µg of total cellular RNA. Open symbols indicate undetectable sam-
ples and report an estimated value calculated as 50% of a detection limit per sample. The 
detection limit depended on the amounts of cellular RNA and therefore differed between 
samples. The medians are represented. Data sets were analysed using a paired, nonparame-
tric Wilcoxon test. p<0.05 was considered statistically significant. SAHA3 vs mock3 p=0.1875; 
CD3+CD28-3 vs mock3 p=0.3125; SAHA6 vs mock6 p=0.2188; CD3+CD28-6 vs mock6 p=0.2969. 
B) Extra-cellular genomic viral RNA (EC HIV-1 RNA) was quantified using RT-qPCR and reported 
as HIV RNA copy numbers/milliliter of plasma. Symbols and statistics as reported for Figure 
13A. SAHA3 vs mock3 p=0.6875; CD3+CD28-3 vs mock3 p=0.1563; SAHA6 vs mock6 p=0.2969; 






J-Lat 8.4 are responsive to SAHA and Romidepsin treatment 
To explore if MATR3 is a limiting factor to latency reversal we opted for its over-
expression  in J-Lat cells treated with LRAs to induce proviral transcription. 
In our hypothesis  MATR3 overexpression can help full viral particle rescue from 
transcriptionally activated J-lat cells by compensating  the inefficient induction of 
post-transcriptional steps after LRAs treatment. 
To test our hypothesis the J-Lat model can be useful thanks to the immortalized 
cell type, easy to manipulate, and to the presence of a reporter gene within an 
already silent but inducible provirus; nevertheless a major limitation of this 
model is posed by the high levels of MATR3 present within J-Lat cells. 
J-Lat 8.4 cells were stimulated for 48 hours with the following LRAs at the indi-
cated concentrations: 
-SAHA (0,5uM- 1uM- 1,5uM) 
-disulfiramin  (5uM) 
-Ingenol B (0,4uM) 
-JQ1 (0,5uM) 
-Romidepsin (0,006uM - 0,0175uM - 0,026uM) 
The reported concentrations were selected referring to literature; TNFa 
(30ng/ml) served as a positive control. 
Responsiveness to drug treatment was evaluated in terms of both GFP expres-
sion by FACS analysis and US-HIV mRNA quantification by qPCR. 
As shown in Figure 14A, J-lat cells strongly respond to Romidepsin treatment at 
both concentration tested while transcriptional induction occurred with SAHA 
only at the higher concentration used; a weak transcriptional induction is also 
observed in response to Ingenol B. 
Results obtained from FACS analysis (Figure 14B) were confusing since not sig-
nificant increase in the percentage of GFP+ cells was observed even with the 
drugs which showed increased US mRNAs transcription from the qPCR analysis, 











MATR3 overexpression doesn’t help full viral particle rescue in combination to 
LRAs in J-lat 8.4 
J-lat 8.4 cells were transduced with lentiviruses to overexpress (OVER) or not 
(CTRL) MATR3, kept under blasticidin selection for 2 weeks and then stimulated 
with the above mentioned LRAs for 48 hours. 
Full viral particle rescue was evaluated by p24 ELISA quantification in the cell cul-
ture media. 
No significant difference was observed after transcriptional induction of the pro-
virus in cells treated to overexpress MATR3 compare to the control in terms of 
full viral particle rescue (Figure 15).  
 
 
FIG.14- SAHA and Romidepsin rescue viral transcription in J-Lat8.4 
J-Lat 8.4 cells were stimulated for 48 hours with different LRAs as indicated in Materials and 
Methods. Viral transcription was assessed by real time PCR quantification of the US RNAs (A) 
or by cytoflorimetric analysis of the GFP+ cells (B). US RNAs are normalized to GAPDH and ex-













MATR3 overexpression is not occurring efficiently in J-lat 8.4 
Since we couldn’t detect any positive effect to latency reversal from the combi-
nation of MATR3 overexpression to LRAs treatment, we hypothesized that the 
high basal level of MATR3 within J-Lat 8.4 could make less appreciable any affect 
on viral replication related to an additional increase in MATR3 protein level. 
We checked the effective amount of MATR3 within OVER or CTRL J-lat 8.4 and 
surprisingly find out that even upon efficient expression of the exogenous  flag-
tagged version of MATR3 after lentiviral transduction, the overall amount of this 
factor was not increased both at protein and RNA level (Figure 16).    
FIG.15- MATR3 overexpression  doesn’t enhance viral rescue in LRAs-treated J-Lat 8.4 
J-Lat 8.4 cells culture  transduced with a lentivector to overexpress MATR3 (OVER) or with a 
control lentivector (CTRL) were grown under blasticidin selection. and stimulated for 48 hours 
with different LRAs as indicated in Materials and Methods.  Full viral particle rescue was as-






We concluded that  J-lat 8.4 finely controlled the levels of MATR3  when an addi-
tional amount of the factor is provided exogenously in a way to minimize the 
variation in its total amount. 









FIG.16- MATR3 overexpression  is not efficiently achieved in J-Lat 8.4 
J-Lat 8.4 cells culture  transduced with a lentivector to overexpress MATR3 (OVER) or with 
a control lentivector (CTRL) were grown under blasticidin selection. Whole cell lisates were 
analysed by immunoblot to assess the expression of the exogenous flag-tagged MATR3 
(FLAG) and the total levels of MATR3; B-actin is the loading control. Western Blot quantifi-
cation is obtained by two different experiments and relative levels of MATR3 are expressed 
as fold change to MOCK. The level of MATR RNA measured by real time-qPCR are norma-







J-Lat 6.3 are responsive to SAHA treatment 
The limitation faced with the attempt to overexpress MATR3 within J-Lat 8.4 lead 
us to change the clone of J-Lat used and repeat our test in J-Lat 6.3. 
In this case we focused on a single drug, SAHA, which was tested at three con-
centration as before( 0,5uM- 1uM- 1,5uM); 48 hours post-stimulation transcrip-
tional induction of the provirus was assessed checking  both  GFP expression by 
FACS analysis and US-HIV mRNA transcription by qPCR. J-Lat 6.3 were found to 













FIG.17- SAHA rescues viral transcription in J-Lat6.3 
J-Lat 6.3 cells were stimulated for 48 hours with different concentration of SAHA. Viral tran-
scription was assessed by real time PCR quantification of the US RNAs (A) or by cytoflorimetric 







MATR3 overexpression in not occurring efficiently in J-Lat 6.3 
J-Lat 6.3 cells were transduced with a lentivirus to deliver the flag-tagged MATR3 
(OVER) or with a control lentivirus (CTRL) and kept under blasticidin selection for 
2 weeks; the effective amount of MATR3 within the cells was checked by both 
immunoblotting and qPCR. 
As observed for J-Lat 8.4 even upon efficient expression of the exogenous flag-
MATR3 the overall amount of the factor was not increased (Figure 18).  
 
                                  
 




FIG.18- MATR3 overexpression  is not efficiently achieved in J-Lat 6.3 
J-Lat 6.3 cell culture  transduced with a lentivector to overexpress MATR3 (OVER) or with a 
control lentivector (CTRL) were grown under blasticidin selection. Whole cell lisates were 
analysed by immunoblot to assess the expression of the exogenous flag-tagged MATR3 
(FLAG) and the total levels of MATR3; B-actin is the loading control. Western Blot quantifica-
tion is obtained by two different experiments and relative levels of MATR3 are expressed as 
fold change to CTRL. The level of MATR RNA measured by real time-qPCR are normalized to 






Development of a model of latency based on resting primary PBLs 
As suspected J-Lat cell line turned out to be an unsuitable model to verify our 
hypothesis about the combinatorial effect of MATR3 overexpression and LRAs. 
The problem seems related to the already high levels of MATR3 in these cells 
that cannot be up-regulated further by overexpression. Indeed an eventual posi-
tive effect on latency reversal related to an increased amount of MATR3 could be 
masked under condition in which such factor is not limiting. 
With the aim to verify our hypothesis in a proper and more physiological cellular 
model we started to work on the set up of a model of latency based on the direct 
infection of resting primary PBLs. 
The task to isolate latently infected cells directly from the blood of HIV+ patients 
is not feasible to our purpose because of the extremely low number of infected 
cells carrying an intact and inducible silent provirus: it has been estimated that 
out of 1 million of CD4+ T cells isolated from the blood of an HIV+ patient only 
10-100 cells contain a replication-competent provirus (Eriksson et al., 2013; Ho et 
al., 2013) 
To overcome this limitation several model of latency based on the ex-vivo infec-
tion of primary PBLs have been proposed by different laboratory during the past 
years. 
Given the refractory of quiescent PBLs to HIV-1 infection, the majority of these 
models require a step of cellular activation prior to infection to render the proc-
ess more efficient: the infected cells should be then left in culture for a reason-
able time to allow a complete reversion to a resting state. 
To make an estimation of the time required by activated PBLs to revert to a rest-
ing phenotype we activated primary PBLs with PHA (3ug/ml) and IL-2 (20U/ml) 
for 4 days; cells were then washed to remove the activation stimuli and cultured 
in IL2 alone. The activation status of CD4+ T cells subset was monitored by check-
ing the expression of the activation markers CD69 and HLA-DR by FACS analysis. 
As shown in Figure 19, PHA addition resulted in almost 40% of cells expressing 
one or both the activation markers. Unfortunately once activated these cells 
hardly come back to a complete resting phenotype: a big percentage of them (~ 
25% in our analysis) still express activation markers after 14 days in culture. 

















The approach based on pre-activated primary PBLs have the obvious advantage 
to facilitate the manipulation of these cells by increasing the efficiency of both 
infection and lentiviral transduction; nevertheless a major limitation to our pur-
pose is represented by the fact that cellular activation induces MATR3 levels 
(Figure 8; Mohammadi et al., 2014) thus rendering this factor not more limiting 
in such a cellular context. 
This consideration along with the limitation to have a real quiescent environment 
lead us to abandon the model based on pre-activated PBMCs and focus more on 
the direct infection of resting primary PBLs.   
Two main features would render this model on resting PBLs ideal: the limiting 
levels of MATR3, which we know to be unaffected even by LRAs stimulation, and 
a more physiological and reliable context of latency.   
In a setting of latently infected resting PBLs we are going to combine transcrip-
tional reactivation induced by SAHA treatment for 72 hrs to post-transcriptional 
stimulation achieved by MATR3 overexpression through lentiviral transduction; 
this would provide us the proof of concept that MATR3 is not only a positive 
regulator of viral replication but is also a limiting factor in reactivation from la-
tency in cells forming the viral reservoir. 
The set up of such a model would consist of three main step: MATR3 overexpres-
sion, HIV-1 infection and SAHA stimulation to reactivate the provirus. 
SAMHD1 depletion doesn’t affect the resting state of primary PBLs 
Resting PBLs are refractory to HIV-1 infection given the presence of restriction 
factors which counteract the process. Among them SAMHD1 proved to block the 
very first steps of viral replication by depleting the pool of dNTPs available within 
the cytoplasm of the host cell to allow the retrotranscription of the viral genome. 
FIG.19- The majority of PHA-activated PBLs doesn’t revert to resting state 
Resting primary PBLs isolated from healthy donors were activated with PHA-IL2 as described 
before; after  4 days PHA was removed and the cells cultured in IL2 alone. Cytofluorimetric 
analysis was done at days: 0 (after PHA removal), 8, 14. Cells were stained with BV421-






In several reports it was shown how the depletion of SAMHD1 can alleviate the 
restriction to HIV-1 infection from resting PBLs: the retroviral factor Vpx was 
found to specifically degrade SAMHD1 through the proteasomal pathway. 
To deliver Vpx within resting PBLs SIVmac-based Viral Like Particles containing 
Vpx (Vpx-VLPs) are available. 
VSVG-pseudotyped Vpx-VLPs were used to treat resting PBLs for 24 and 48 
hours; SAMHD1 depletion was then assessed by immunoblotting and revealed an 
efficient removal of the restriction factor within 48 hours (Figure 20A). We asked 
if the depletion of SAMHD1 could somehow affect MATR3 protein levels and 
confirmed by immunoblotting that this was not the case (Figure 20B). 
    
 




Next we wanted to assess if treatment with Vpx-VLPs can alter the activation 
status of resting PBLs:  2x10^6 resting PBLs isolated from healthy donors were 
treated (PBL-Vpx)  with 12ng of Vpx-VLPs or left untreated (PBL); 6 days post 
FIG.20- SAMHD1 depletion doesn’t affect MATR3 expression  
Resting primary PBLs isolated from healthy donors were treated with VSV-G pseudotyped Vpx-
VLPs for 24 and 48 hours. Whole cell lysates were blotted for SAMHD1 (A) and MATR3 (B); B-






treatment the resting status of the cells was checked by FACS through the stain-
ing for the activation markers CD69 and HLA-DR. 
As shown in Figure 21, CD4+T lymphocytes don’t increase the expression of early 












FIG.21- SAMHD1 depletion doesn’t activate resting PBLs  
Resting primary PBLs isolated from healthy donors were treated with VSV-G pseudotyped Vpx-
VLPs. Cytofluorimetric analysis was done 6 days post treatment; cells were stained with APC-







MATR3 overexpression is not achieved along with HIV-1 infection 
SAMHD1 depleted cells were infected with 450ng of a full length clone of HIV-1 
containing the GFP reporter gene under the CMV promoter (kindly provided by 
Dr.Monsef Benkirane). The presence of the GFP gene under the control of CMV 
allow the constitutive expression of the reporter even under silencing condition 
at the LTR viral promoter thus allowing the identification of all the infected cells. 
8 hours post infection PBLs were transduced with 600ng of lentivirus to express 
the flag-MATR3 and cultured in IL-2 containing media. 
5  days post infection/transduction cells were analysed by FACS to assess the ef-
ficiency of infection (p24 staining and GFP) and the efficiency of lentiviral trans-
duction and flag-MATR3 expression (flag staining). 
The markers for HIV-1 infection gave contrasting results: an high percentage of 
p24 positive cells was detected while the GFP expression was not observed (Fig-
ure 22). 
Limitation in the detection of GFP signal were frequently encountered even in 
other experiments with the same virus which probably made the p24 staining 
more reliable to assess the efficiency of infection, which remained anyway still 
uncertain to be precisely defined. 
Unfortunately, flag-MATR3 was not detected after lentiviral transduction as 
showed by the anti-flag staining (Figure 22). 
Several attempts were conducted to optimize the step of lentiviral transduction 
by changing both the concentration of lentivirus used and the timing of transduc-
tion but all of them gave disappointing results: the concomitant events of HIV-1 
infection and MATR3 overexpression didn’t occur efficiently in resting primary 

























FIG.22- MATR3 overexpression is not achieved along with HIV-1 infection  Resting prima-
ry PBLs isolated from healthy donors were treated with VSV-G pseudotyped Vpx-VLPs as 
before. 48 hours after treatment , SAMHD1-depleted PBLs were  transduced with the lenti-
vector to express flag-MATR3 (OVER) and infected with a replication competent HIV-1 con-
taining the GFP as a reporter gene. Cytofluorimetric analysis was done 5 days post treat-
ment; cells were stained with APC-Cy7-antiCD3, BV510-antiCD4, PE-Cy7-antiCD69, BV421-








The HIV-1 viral life cycle is a complex process which relies on the host cellular 
machinery. Proviral transcription and RNA metabolism occur with the concerted 
action of cellular pathways and viral factors, co-evolved to fully exploit the host 
environment to guarantee its replication. 
To avoid the translation of defective mRNAs which would result in the produc-
tion of possibly deleterious proteins, the cellular “quality control” pathway of 
nonsense-mediated decay along with a finely regulated export pathway, assure 
that only properly processed mRNAs are exported to the cytoplasm.  Thus the 
presence of viral intron-containing mRNAs at their mature stage could represent 
a major obstacle for the virus to the completion of the first steps of viral gene 
expression: unspliced transcripts should be retained in the nucleus and targeted 
for degradation or sequestration. To overcome this obstacle HIV-1 has evolved 
the viral factor Rev which is involved in the specific pathway of intron-containing 
mRNA export. To this aim Rev engages an alternative route for viral mRNA export 
which ultimately involves the CRM-1 transport receptor, used by the eukaryotic 
cells to allow cytoplasmic translocation of protein cargos and specific type of 
RNAs. 
The exact pathway which goes from Rev multimerization on viral mRNA to CRM1 
recruitment has not been fully elucidated and some steps still remain elusive; 
thus a better understanding of the Rev interaction with the host proteins during 
the export process would help to identify the crucial host factors involved and 
characterize better the details of this process. With this aim it was exploited in 
our laboratory an approach based on the immunoprecipitation of viral RNA cou-
pled to a mass-spectrometry analysis which allow the identification of the host 
protein MATR3 as an element of the Rev/RNA complex (Kula et al., 2011).  
MATR3 is a component of the nuclear matrix, a complex structure which organ-
ize both spatially and functionally the nucleus: for this reason MATR3 can be in-
volved in a plethora of role ranging from structural definition of discrete com-
partments to functional involvement in genome expression (Bode et al., 2003; 
Coelho et al., 2015; Salton et al., 2010, 2011). 
The literature analysis on MATR3 revealed that this factor has been related to 
several processes in mRNA metabolism: its involvement in defective mRNA re-





and Carmichael, 2001)  while its action on alternative splicing regulation was as-
sociated to PTB (Coelho et al., 2015), thus suggesting that MATR3 can be re-
cruited to different complexes and the factors engaged help defining its action. 
In the context of host-virus interaction, MATR3  was  reported to have a role in 
retroviral infection. Both for Moloney Murine Leukemia Virus (MoMu-LV) and 
HIV-1 it was found that MATR3 is a negative regulator of ZAP-mediated retroviral 
restriction since its depletion resulted in a strengthened antiviral activity (Erazo 
and Goff, 2015). Specifically for HIV-1, it was previously reported  by us and other 
groups, that MATR3 positively affect  viral replication (Kula et al., 2013; Yedavalli 
and Jeang, 2011): thus my thesis work aims to a better definition of the involve-
ment of MATR3 in the context of HIV-1 infection both in the acute and the latent 
phase. 
To point out a functional role for MATR3 during HIV-1 acute infection, we 
knocked-down this factor in Jurkat cells: a first striking observation we made is 
that MATR3 depletion in HIV-1 infected Jurkat cells results in a dramatic drop of 
viral replication. Notably we could recapitulate the same phenotype also in 
MATR3 depleted primary PBLs in the context of acute infection confirming that 
MATR3 is an essential factor to HIV-1 replication. 
Our preliminary investigations suggested  that MATR3  is recruited after tran-
scription and  interacts with Rev in an RNA-dependent manner. Thus to better 
characterize the effective role of MATR3 in the viral life cycle we further investi-
gated the outcome of MATR3 depletion on HIV-1 transcription and mRNA me-
tabolism.  
By infecting Jurkat cells with an HIV-1 vector containing the luciferase gene as a 
reporter for transcription we could confirm that MATR3 depletion didn’t affect 
proviral transcription during acute infection meanwhile we observed an intrigu-
ing effect on viral mRNA distribution. Intron-containing viral transcripts accumu-
lated in the nucleus of infected Jurkat cells deprived of MATR3 and consequently 
intracellular viral protein production was impaired; on the other hand fully 
spliced viral transcripts were not affected and no imbalance in their nucleo-
cytoplasmic distribution was observed. We therefore suggested that the effi-
ciency of Rev-mediated export was compromised by MATR3 depletion thus af-





To verify our hypothesis on the role of MATR3 as a Rev co-factor during HIV-1 
acute infection we sought to test if an increase in MATR3 protein levels could 
boost mRNA export and viral replication. 
Exogenous delivery of a flag-tagged MATR3 into infected lymphocytes resulted in 
the effective increase in the total amount of MATR3 and, as expected, this 
caused an effect specifically on US-mRNA metabolism, while MS mRNAs were 
not affected. In particular, intron-containing mRNAs showed a reduced nuclear 
level, without a concurrent increase in their cytoplasmic localization: this obser-
vation can suggest either an enhanced export or a reduced stability of this 
mRNAs. 
It was previously reported by Erazo and Goff (Erazo and Goff, 2015)  that changes 
in the levels of MATR3 can affect HIV-1 mRNAs stability; in particular they no-
ticed that MATR3 knockdown strengthen the ZAP-mediated degradation of both 
MS and US viral transcripts thus leading to a dramatic drop in viral replication. 
In our case we observed that the reduction of viral mRNAs concentration oc-
curred upon MATR3 overexpression and only in the nucleus; moreover the effect 
we reported was specific for US mRNAs while MS ones were unaffected.  
Nevertheless, to rule out a possible effect of MATR3 overexpression on viral 
mRNAs stability we checked the level of intracellular viral proteins and the viral 
particle production. The increase in intracellular Gag and in viral particle produc-
tion associated to MATR3 overexpression excluded any effect on mRNA stability 
and confirmed that MATR3 is a positive regulator of HIV-1 replication which acts 
as a Rev-cofactor to mediate the nuclear export of US viral mRNAs. 
The discovery of new cellular factors involved in HIV-1 replication contributes to 
broaden the knowledge of the mechanisms behind viral infection. From the first 
contact with the target cell to the release of new virions every step of the viral 
life cycle is carried out with the concerted action of different host factors and 
thus any perturbation in their optimal function could greatly affect the progres-
sion of viral replication. 
It’s easy to understand how the establishment of post-integrative latency within 
infected cells requires a peculiar cellular environment in which the transcrip-
tional and post-transcriptional steps of viral replication are somehow defective. It 
is known that resting PBLs which mainly compose the HIV-1 viral reservoir exhibit 





PBLs: thus the better comprehension of the phenomena of latency can’t be sepa-
rated from a deeper understanding of the cellular context where it is established. 
Extensive studies have been conducted to reveal the transcriptional blocks pre-
sent in latently infected cells. The epigenetic modifications to chromatin at the 
integration site are known to play an important role in maintaining a silent provi-
rus: both increased methylation and inadequate acetylation contribute to render 
the LTR sites inaccessible to the transcription complex (Jiang et al., 2007; Marban 
et al., 2007; Pearson et al., 2008; Tyagi and Karn, 2007; Van Lint et al., 1996). 
Moreover, the majority of the cellular factors involved in transcription are ex-
pressed at limiting levels or kept in an inactive state thus rendering the process 
inefficient: the suboptimal nuclear translocation of NF-kB  and the sequestration 
of the elongation factor P-TEFb into an inactive complex play a crucial role in the 
transcriptional silencing of the provirus (Budhiraja et al., 2013; Fujinaga et al., 
2004; Michels et al., 2004; Ping and Rana, 1999; Zhong et al., 2002). 
The detailed characterization of the transcriptional blocks behind proviral silenc-
ing is the starting point of the so-called “shock and kill” strategy, one of the most 
intriguing therapeutic approach proposed to clear the viral reservoir. The “shock 
and kill” strategy proposes that the clearance of the viral reservoir can be 
achieved by reverting the latent state of the virus through its transcriptional in-
duction: the return into active replication would render the infected cells visible 
to the host immune system leading to their targeting and removal. To achieve 
this goal several drugs, collectively called the Latency Reversal Agents (LRAs), 
have been proposed.  The transcriptional induction is achieved by different 
mechanisms, from the addition or removal of selective epigenetic histone modi-
fication to the direct stimulation of the activity of the factors involved in the 
transcriptional pathway. The panel of LRAs includes Histone Methyltansferase 
Inhibitors (HMTIs), Histone Deacetylase Inhibitors (HDACIs), NF-kB activators and 
P-TEFb inducers; in vitro investigations with single or combination of these drugs 
reveal that most of them were able to induce in-vitro transcription at the LTR 
site.  
Despite the efficient removal of transcriptional blocks an effective rescue of the 
full virus from latent cells is still lacking with most of the drug tested suggesting 
that other limitations impede the completion of the viral life cycle (Darcis et al., 





The contribution of post-transcriptional steps to the maintenance of latency has 
been poorly investigated during the past years even though some crucial discov-
eries started to unveil the possible role played by factors involved in mRNA me-
tabolism to the phenomena (Sarracino and Marcello, 2017). 
Several primary cell models have been used to investigate post-transcriptional 
latency: in the CD4+ T cell model used by Pace et al. (Pace et al., 2012) it was 
found that reduced level of MS mRNAs were associated to the nuclear retention 
of US ones, suggesting how inefficient splicing and export of viral mRNAs can 
contribute to latency. In the model of Saleh et al. (Saleh et al., 2011)  in which 
resting primary CD4+ T cells were treated with CCL19 prior to infection was 
found that the levels of US mRNAs were reduced possibly due to a nuclear reten-
tion or a cytoplasmic degradation of MS ones. 
Importantly, in the work of Lassen et al. (Lassen et al., 2006)  the ectopic expres-
sion of the polypyrimidine-tract binding protein (PTB) in resting CD4+ T cells from 
HIV+ patients was able to rescue the proper export of both fully and partially-
spliced viral transcripts underlining the role that limiting levels of host factors in-
volved in mRNA metabolism can play in the maintenance of latency. 
The transcriptomic analysis of resting PBLs revealed that most of the factors in-
volved in mRNA splicing, stabilization and export are poorly expressed unless an 
activation stimulus is provided thus suggesting how the maintenance of a quies-
cent state rely also on the limitation in mRNA processing (Mohammadi et al., 
2014). 
We found interesting that factors like PSF, PTB and MATR3 were shown to be 
poorly expressed in resting cells: to assess the actual expression of those factors 
in quiescent PBLs and CD4+ T cells we checked their protein level prior and post-
activation with PHA and we confirmed their barely detectable basal expression, 
which is induced only after activation. 
To better characterize the modulation of MATR3 level in the cellular context 
found in latency and upon exposure to drugs for AIDS treatment we sought to 
test if drugs selected from the panel of LRAs have any effect on the induction of 
MATR3 expression. To this aim we stimulated primary PBLs from healthy donors 
with the PTEN inhibitor Disulfiramin, the two histone deacetilase inhibitor SAHA 
and Romidepsin  or the BET-inhibitor JQ1 in combination to the PKC agonist In-
genol B and observed that none of the tested drugs or combination was able to 





To extend this observation to the actual context of latent HIV-1 infection we re-
peated this test in PBLs isolated from aviremic HIV+ patients under antiretroviral 
therapy (ART). We could confirm that HIV-1 infected primary resting PBLs treated 
with LRAs still express limiting amount of MATR3 and that only cellular activa-
tion, in this case by TCR stimulation by anti-CD3/anti-CD28 beads, is able to raise 
MATR3 protein levels, indicating that the mode of induction is essential. 
The assessment that MATR3, which we previously identified as a crucial factor 
for HIV-1 replication, is poorly expressed within cells composing the viral reser-
voir lead us to wonder about a possible involvement of this host factor in the 
maintenance of latency. Limiting level of MATR3 and other factors involved in 
mRNA processing and export could be responsible for the failure of the attempts 
to efficiently rescue the full virus from latent cells under condition in which the 
LRAs render the virus transcriptionally active.  
To begin our investigation on the possible role of MATR3 in the context of viral 
latency we sought to verify if it’s depletion in the well-established latency model 
of J-Lat has any affect on viral reactivation. We transduced J-Lat 8.4 cells with a 
lentivector coding for a shRNA targeting MATR3 and confirmed an efficient de-
pletion of the factor. Upon administration of TNFα, we could confirm by checking 
GFP expression, that transcriptional activation of the integrated provirus oc-
curred efficiently and that MATR3 removal was not affecting this process. Inter-
estingly we could observe that both intracellular Gag and virion quantification in 
the culture media were decreased in MATR3- depleted J-lat cells: the defect on 
full viral particle production in condition of efficient viral transcription clearly in-
dicated that MATR3 depletion affected the post-transcriptional steps of latency 
reversal. 
The results obtained from  J-lat cells supported our hypothesis about the neces-
sity of post-transcriptional factors such as MATR3 to guarantee that, the tran-
scriptional input to viral reactivation provided by TNFα or other drugs, lead to a 
complete replication cycle. 
In this view, a revised approach to the “shock and kill” strategy would include 
drugs capable of inducing those processes involved in post-transcriptional RNA 
processing to remove any block to full viral reactivation. 
In our previous tests with LRAs we could observe that MATR3 levels remained 
limiting after treatment with all the drugs. Among those drugs we focus on SAHA 





clinical use and we extended our observation to investigate the effect that SAHA 
alone has on the latency reversal. 
To this aim we stimulated PBLs from HIV+ patients with 0,5uM of SAHA, a dosage 
within the window of the plasmatic concentration usually found in treated pa-
tients. The latent virus was responsive to SAHA and its transcription was effi-
ciently restored as was stated by the appearance of intracellular viral transcripts 
which range levels comparable to the one obtained by cellular activation. Inter-
estingly, the transcriptional induction rescued after stimulation with SAHA was 
not associated to full virion production, contrary to the appearance of complete 
viral particles observed after cellular activation by TCR stimulation. 
Synergistic combination of LRAs have been tested with the aim to achieve a 
stronger effect on latency reversal (Darcis et al., 2015). We suggest that a new 
intriguing approach would be to combine stimuli acting at different stages: a po-
tent transcriptional inducer to revert transcriptional silencing to a stimulus acting 
post-transcriptionally to assure that nascent viral RNAs are efficiently processed. 
We believe it would be interesting to test if the restoration of proper MATR3 
levels within latently infected cells could help overcome the limitation to full 
virion production faced upon SAHA administration.  
We started working on a suitable cellular model of latency to test our hypothesis: 
ideally we would need a cellular setting in which MATR3 levels are limiting in a 
way to be able to obtain a major increase in its total amount by delivering an ex-
ogenous version of the factor with the help of a lentiviral tool. 
Clearly the best cellular model  to our purpose would be the one provided by 
resting infected primary PBLs because of the almost intact and physiological la-
tency environment; moreover we could previously assess that MATR3 levels are 
limiting under such conditions and not affected by SAHA administration. 
Several protocols are available to set up a latency model based on primary PBLs: 
however the majority of them require a previous step of cellular activation to in-
crease the efficiency of HIV-1 infection. Infected cells should be then cultured for 
a reasonable time in absence of any activation stimulus to allow a complete re-
version to a quiescent phenotype (Pace et al., 2011; Spina et al., 2013).  
To estimate the time in culture needed by  PHA-activated PBLs to come back to 
the resting state we monitored their activation status after PHA removal by 





three weeks. We observed that once activated, primary PBLs harshly come back 
to the resting state and a substantial part of them still express activation markers 
after two weeks from PHA removal; an additional week of culture only resulted 
in cell death. 
Another major disadvantage to the use of a model based on pre-activated PBLs 
to our purpose, is that  cellular activation increases MATR3 levels thus rendering 
this factor not more limiting in this cellular context. In the transcriptomic analysis 
provided by the group of Talenti (Mohammadi et al., 2014) in which cellular gene 
expression is analysed in latently infected cells from a well-described latency 
model based on  CD4+ T cells, it was found that the levels of different factors, 
and between them MATR3, remained sub-limiting after cellular activation, even 
after the long cellular culture used to allow the establishment of latency.  
Considering the limitation in restoring a proper quiescent state and the modula-
tion in MATR3 levels occurring after cellular activation, we abandoned the idea 
to use a model based on pre-activated PBLs for our purpose. 
An alternative approach to set up a latency model in primary PBLs propose the 
direct infection of resting cells: two major advantages of this model consist in the 
preservation of the actual quiescent cellular context in which the viral latency is 
established and in the maintenance of limiting levels of MATR3. 
Nevertheless several restrictions counteract HIV-1 viral infection of resting PBLs 
in vitro. 
 A major block to HIV-1 infection is constituted by the presence of the host factor 
SAMHD1 which acts as a potent restriction factor to viral infection. SAMHD1 is a 
cellular nuclease which exhibit a phospohydrolase activity by removing a phos-
phate group from deoxynucleoside triphosphate (dNTPs).  Its action results in the 
reduction of the dNTPs pool, which, in turns affect the efficiency of reverse tran-
scription during retroviral infection; the antiviral effect of SAMHD1 is more pro-
nounced in resting cells because of the already exiguous pool of dNTPs (Descours 
et al., 2012; Goldstone et al., 2011). 
It was shown that SAMHD1 depletion enhances HIV-1 infection: thus its removal 
from resting PBLs could provide a useful strategy to render these cells more 
permissive to viral infection in vitro. Recently it was discovered that the retroviral 





notably this factor is not expressed by HIV-1 but only by other retroviruses such 
as HIV-2 and SIV (Hofmann et al., 2012; Laguette et al., 2011). 
To deliver the Vpx factor within resting PBLs a viral tool based on SIVmac back-
bone have been developed: these SIVmac-derived Viral Like Particles containing 
Vpx (Vpx-VLPs) can be pseudotyped with the VSV envelope protein  (VSV-G) to 
increase the efficiency of delivery (Geng et al., 2014; Nègre et al., 2000). 
We decided to take advantage of this strategy to render resting PBLs more per-
missive to viral infection, to infect these cells with HIV-1 to establish a model of 
latency and in this model to combine the overexpression of MATR3 to the treat-
ment with LRAs to finally test if the two approach can act in synergy to revert vi-
ral latency. 
We treated resting PBLs with VSV-G pseudotyped Vpx-VLPs and  we could assess 
an efficient degradation of SAMHD1 occurring in 48 hours; to verify if the treat-
ment with Vpx-VLPs could somehow affect MATR3 expression we simultaneously 
checked the levels of MATR3 protein and assure that there was no effect on its 
expression. To exclude that the treatment with Vpx-VLPs alter the quiescent 
state of the cells we analysed the expression of early (CD69) and late (HLA-DR) 
activation markers before and after treatment; we confirmed that incubation 
with viral like particles and Vpx delivery didn’t activate the resting PBLs. 
Resting PBLs, treated with Vpx-VLPs to be more permissive to viral infection, 
were infected with a replication competent HIV-1 containing the additional GFP 
gene as a reporter for viral infection: the GFP gene is cloned under the CMV 
promoter in a way to allow its expression even under condition where the tran-
scription at the LTR is silenced.  
To decide the concentration of lentivirus to use to deliver the flag-MATR3 within 
resting PBLs, we conducted some preliminary test by checking the efficiency of 
FLAG-MATR3 expression using increasing amount of lentivector. The concentra-
tion selected was the lower one at which we started to detect the FLAG-MATR3 
expression since we observed a marked cellular toxicity upon lentiviral transduc-
tion. The transduction with the lentivector to deliver the flag-tagged MATR3 was 
performed the same day of the infection with the aim to reduce the time passing 






The efficiency of infection was evaluated by cytofluorimetric analysis checking 
for the expression of GFP and intracellular p24. The first thing we noticed is that 
the percentage of GFP positive cells doesn’t correspond to the percentage of p24 
positive ones which suggest that one of the two markers is not reliable to esti-
mate the rate of infected cells. Problems in the detection of GFP signal were fre-
quently encountered  in different experiments using the same virus: thus the p24 
staining was probably more reliable to assess the efficiency of infection. Never-
theless the percentage of p24 positive cells is so high that likely could be overes-
timated due to a residual contamination with the input virus used for the infec-
tion: thus the exact percentage of infected cells remained still uncertain. 
The efficiency of lentiviral transduction was assessed by cytofluorimetric analysis 
of the intracellular FLAG: unfortunately no FLAG expression was detected con-
comitantly to HIV-1 infection under the tested condition. Attempts to increase 
the time frame occurring between the viral infection and the lentiviral transduc-
tion to 24 hours didn’t help achieving a better efficacy of the two process simul-
taneously.  
In conclusion  we faced technical issues, especially related to the expression of 
the exogenous FLAG-MATR3, which don’t allow us to set up a proper model of 
latency based on the direct infection of resting PBLs to verify the actual contribu-
tion of MATR3 to the reactivation of the latent provirus. 
Since we had to put aside the idea to use primary cells for our latency model we 
evaluated the possibility to utilize the classic latency model of J-Lat. Although  
the J-Lat cell line can represent a very useful tool for the study of latency thanks 
to the immortalized cell type, easy to manipulate, and to the presence of a re-
porter gene within an already silent and inducible provirus, we had some hesi-
tancy to the employment of the J-Lat model to our task. 
 A major doubt arises from the consideration that J-Lat cells are not limiting in 
the levels of MATR3: thus it  is necessary to keep in mind that the high basal level 
of the factor could make less appreciable any affect on viral replication related to 
an additional increase in MATR3 protein level. The general approach would re-
main unchanged: transcriptional induction provided by LRAs stimulation would 
be combined to MATR3 overexpression obtained by lentiviral transduction to de-
liver its FLAG-tagged version. 
It is known that J-Lat 8.4 are responsive to treatment with TNF-α, a cytokine able 





screening with different LRAs was thus necessary to assess if J-Lat 8.4 are re-
sponsive to any other of the tested drugs. We stimulated J-Lat 8.4 cells with 
SAHA, Romidepsin, Disulfiramin, Ingenol and JQ1 at different concentration; the 
transcriptional induction of the virus was assessed by checking both the GFP ex-
pression and the transcription of the unspliced viral mRNAs: we found that both 
Romidepsin and SAHA are able to rescue the transcription of the latent virus. 
Next we combined the treatment with the above mentioned drugs to the over-
expression of MATR3: J-Lat 8.4 cells transduced with a lentivector to express the 
FLAG-MATR3 were stimulated for 48 hours with the different drugs and then we 
evaluated the effect on full viral particle rescue by looking at the viral titre in the 
culture media. Unfortunately we couldn’t detect any positive effect to latency 
reversal from the combination of MATR3 overexpression to LRAs treatment. 
We then hypothesized that, as supposed, the high basal level of MATR3 within J-
Lat 8.4 could mask any  effect on viral replication related to an additional in-
crease in MATR3 protein level. 
We checked the effective amount of MATR3 within these cells and surprisingly 
find out that even upon efficient expression of the exogenous  flag-tagged ver-
sion of MATR3 upon lentiviral transduction, the overall amount of the factor was 
not increased. This observation was quite unexpected and we suppose that the 
overall amount of MATR3 is finely regulated within J-Lat 8.4 cells in a way to 
minimize drastic increase in its expression.  
To verify if this limitation in efficiently increasing MATR3 levels was specific for J-
Lat 8.4, we tried to recapitulate the same approach in a different J-Lat clonal cell 
line, the J-Lat 6.3. 
First of all we verified that this cell line was suitable to our purpose by checking 
the effect of the previously screened LRAs on viral transcription: we could con-
firm that J-Lat 6.3 cells responded to treatment with SAHA and Romidepsin by 
inducing high levels of viral mRNA transcription. Once confirmed their respon-
siveness to LRAs, we transduced J-Lat 6.3 cells with a lentivector to express the 
FLAG-MATR3 and checked the effective expression of the exogenous factor. We 
observed again that, even upon efficient delivery and expression of the exoge-
nous MATR3, the total amount of the protein was unaffected and no significant 





Unfortunately we couldn’t succeed in the attempt to overexpress MATR3 within 
J-Lat cells since it seems that the overall amount of this factor are finely regu-
lated to avoid drastic variation in its expression. 
In conclusion we couldn’t find a suitable model of latency, either based on pri-
mary or immortalized cells, in which establish the proper condition to verify if 
the limiting levels of MATR3 are responsible for the post-transcriptional blocks 
which maintain the virus in its latent state.   
  




CONCLUSION AND REMARKS 
HIV-1 full viral gene expression is achieved with the concerted action of host and 
viral factors. We identified the host protein MATR3, a component of the nuclear 
matrix, as a Rev-cofactor recruited to engage the alternative nuclear export 
pathway through CRM1 to allow the cytoplasmic translocation of viral intron-
containing mRNAs. 
In this work we defined a functional role for MATR3 in the context of acute infec-
tion with a replication competent HIV-1; moreover we provide some evidences 
about the likely contribution of MATR3 to the maintenance of a latent state 
within the viral reservoir. 
We modulate the level of MATR3 both in T cell line and primary PBLs and we 
proved that MATR3 knockdown results in the nuclear retention of unspliced viral 
transcripts thus dramatically affecting viral replication. On the contrary, if MATR3 
levels are increased, the positive input to viral mRNA export enhances not only 
viral protein production but finally leads to a remarkable raise in viral replication. 
We observed that MATR3, like other factors involved in mRNA metabolism, is 
poorly expressed in resting PBLs suggesting that the cellular environment in 
which viral latency is established could rely on limiting levels of these factors to 
maintain the virus in a latent state. Moreover we showed  that the drugs cur-
rently proposed to revert the transcriptional silencing of the virus don’t alter the 
expression of MATR3 which remain limiting throughout the treatment which 
lead to removal of transcriptional blocks. 
Specifically for SAHA, one of the best characterized drug in the panel of the 
tested ones, we showed that the re-establishment of efficient viral transcription 
doesn’t lead to the production of complete viral particles revealing that removal 
of transcriptional blocks is necessary but not sufficient to allow the latent virus to 
come back to active replication. 
Intriguingly this observation uncover an aspect of viral latency, the existence of 
post-transcriptional blocks, which remain mostly elusive and would need further 
exploration to shed some light on what are the critical steps to be targeted to al-
low the virus to leave the latent state. 
We demonstrated in J-Lat cells, a classic model of latency, that MATR3 depletion 
impede the full viral rescue under condition of optimal viral transcription and we 




propose that, due to a block in nuclear mRNA export caused by MATR3 limiting 
levels, the viral cycle get stuck in the production of structural proteins to assem-
ble the nascent virion. 
In this work we lack a direct evidence that the restoration of adequate levels of 
MATR3 within latently infected cells can provide the “post-transcriptional boost” 
to the initial SAHA’s “transcriptional kick” to revert viral latency. 
Despite the technical difficulties we encounter to inspect this last scenario, we 
believe that at this point is essential a further exploration of the post-
transcriptional blocks which render the “shock and kill” approach still unsuccess-
ful. 
A better comprehension of the pathways which are obstructed during the estab-
lishment of the latent state and the discovery of the crucial factors indispensable 
to revert such condition could significantly improve the development of a clinical 
strategy to clear the viral reservoir leading finally to a “sterilizing cure” to effec-








MATERIALS AND METHODS 
CELLS 
Human embryonic kidney 293T cells were grown in Dulbecco’s Modified Eagle 
Medium (DMEM) supplemented with 10% Fetal Bovine Serum (FBS) and 
antibiotics (penicillin/streptomycin). 
Jurkat and J-Lat cells obtained from NIH Research and Reference Reagent 
Program were cultured in Rosewell Park Memorial Istitute medium (RPMI) 
supplemented with 10% FBS and antibiotics. 
Peripheral Blood Mononuclear Cells (PBMCs) and Peripheral Blood Lymphocytes 
(PBLs) were purified from healthy donors’ buffy coat obtained from “Ospedale 
Maggiore of Trieste”.  
PBMCs were purified through Ficoll gradient (Ficoll-Hystopaque Lonza) and 
cultured in RPMI supplemented with 10% heat inactivated FBS and antibiotics. 
After an overnight culture non-adherent PBLs were collected and grown in the 
same media containing only IL2 (20U/ml) to maintain the resting state or IL2 
(20U/ml) and PHA (5ug/ml) to activate them.  
LENTIVIRAL VECTORS  
pLKO.1 lentiviral vectors expressing shRNAs targeting MATR3 or a scramble CTRL 
were obtain from Open Biosystems (TRCN0000074903-904-905-906-907 or 
shCTRL). 
The pWPI-flagMATR3 lentiviral vector was produced by cloning the flag-MATR3 
cDNA into the pWPI plasmid (kindly provided by Gualtiero Alvisi, University of 
Padova). 
Briefly, the flag-MATR3 sequence was amplified by PCR from the pCMV-
flagMATR3 plasmid adding the restriction sites for AscI and MluI at the 5’ and 3’ 
site of the gene respectively. 
The obtained sequence was inserted into the pWPI_BLR  transfer vector digested 
with Asc I and Mlu I and the plasmid was amplified in XL10 gold bacteria. Ampicil-
lin resistant bacterial colonies were screened for the presence of the pWPI-




flagMATR plasmid whose identity was verified by both enzimatic digestion and 
sequencing (Figure 23). 
The VSV-G pseudotyped lentivirus to overexpress MATR3 was tested on Jurkat 
cells and the efficient expression of the exogenous protein was assessed by an 







FIG.23- cloning strategy to obtain the pWPI-flagMATR3 lentiviral vector. The flag-MATR se-
quence containing the restriction sites for AscI-MluI was amplified from the pCMV-flagMATR 
plasmid and cloned into the pWPI vector digested AscI-MluI. Mini prep screening was performed 
by enzimatic digestion with AscI-MluI and the positive clone was checked by sequencing. 
 




                                                
               
 
 
TRANSFECTION AND TRANSDUCTION 
Lentiviral particles to knockdown MATR3 were produced by calcium-phosphate 
transfection of 293T cells with the transfer vector (pLKO-shRNA; pLKO-scramble), 
the packaging plasmid (psPAX2) and the VSV-G coding plasmid (pMD2G), (all 
from Addgene). 
Lentiviral particles to express the flag-tagged MATR3 were produced by co-
transfecting the transfer vector (pWPI; pWPI-flagMATR), the packaging plasmid 
(psPAX2) and the VSV-G coding plasmid (pMD2G). 
Lentivirus-containing supernatant was collected 48 hours post-transfection, 
centrifuged to remove cell debris, filtered through 0,45nm filter and stock at –
80°C. 
When needed lentiviral-containing supernatant was concentrated 100 folds by 
ultracentrifugation at 27000 rpm and quantified by p24 ELISA (Retrotek, 
Zeptometrix). 
To deplete or overexpress MATR3 1x10^6 cells were incubated with the 
lentivirus in 6-well plate for 16 hours; cells were then washed with PBS to 
FIG.24- Validation of the flag-MATR lentiviral vector. Jurkat cells were transduced with the VSV-
G pseudotyped  lentivirus to express the flag-MATR3 (OVER) or with a control lentivector (CTRL) 
and selected by Blasticidin resistance. Whole cell lysates were blotted for FLAG;  B-actin is the 
loading control.  
 




remove unbound lentiviral particles and 24 hours post-transduction cells were 
put under puromicin (1ug/ml) or blasticidin (10ug/ml) selection.  
HIV-1 VIRUS PRODUCTION 
The replication competent HIV-1 virus was produced by calcium-phosphate 
transfection of 293T cells with the full-length HIV-1 clone pNL4.3. 
48 hours post-transfection virus-containing supernatant was collected, clarified 
by centrifugation, filtered through 0,45nm filter and stock at -80°C. Viral titre was 
quantified by p24 ELISA (Innogenetics).  
A replication competent HIV-1 virus containing the GFP reporter gene in frame 
with Nef and under the control of CMV promoter was kindly provided by Dr. 
Monsef Benkirane. 
ANTIBODIES  
For immunoblotting the following antibodies have been used: MATR3 (A300-
590A, Bethyl laboratories, dilution 1:5000), HIV-1 p55 and p24 (HIV-1 p24 sc-
65462, Santa Cruz, dilution 1:250), FLAG (Sigma, dilution 1:5000), B-Actin-HRP 
(Sigma, 1:10000), Vimentin (Cell Signalling, dilution 1:1000), PARP (Enzo Life), 
Hsp90 (Enzo Life), PSF (Sigma P2860, 1:1000), Cyclin T1 (C-20-SC-8128, 1:200), 
PTB (rabbit polyclonal produced in house, 1:1000). 
For cytofluorimetrics analysis the following antibodies have been used: APC-flag 
(Biolegend, 637307, dilution 1:50), RD1-p24 (Beckman KC57-RD1, dilution 1:40), 
APC-Cy7-CD3 (Biolegend, dilution 1:25), BV510-CD4 (Biolegend, dilution 1:25), 
BV421-HLA-DR (Biolegend, dilution 1:25), PE-Cy7-CD69 (Biolegend, dilution 1:25). 
DRUGS AND REAGENTS 
The following drugs have been used: SAHA (SML0061 Sigma), disulfiram 
(PHR1690 Sigma),  
romidepsin (S3020, Selleckchem), JQ1 (2091-1 BioVision).  
IngenolB was kindly donated by Luiz F. Pianowski, Kyolab/Amazônia Fitomedica- 
mentos, Valinhos, Sao Paulo, Brazil. 
Other reagents include: Histopaque – 1077 (10771, Sigma), Polybrene (Sigma-
H9268), Phytohemagglutinin (PHA L1668-5MG, Sigma), Interleukin-2 (H7041, 




Sigma), TNF-α (T0157, Sigma),  Puromycin (ant-pr-1 InvivoGen), Blasticidin (ant-
bl-1 InvivoGen). 
LUCIFERASE ASSAY 
Jurkat cells were infected with 1μg/ml of HIV-1 pNL4.3R-E-luc pseudotyped with 
VSV-G envelope for 4 hours. The infected cells were washed twice and further 
incubated at 37°C for 48 hours.  
48 hour post infection the cells were harvested and lysed in passive lysis buffer 
(Promega) and the levels of luciferase activity were measured by the Single-
Luciferase-Reporter assay (Promega) as directed by manufacturers. For normali-
zation, total protein concentration in each extract was determined with a Bio-
Rad protein assay kit. 
NUCLEAR AND CYTOPLASMIC FRACTIONS 
To separate nuclear and cytoplasmic fractions cells were washed in cold PBS and 
lysate in Buffer A (10mM Tris HCl, 10mM NaCl, 3mM MgCl, 10% glycerol, 0,1% 
NP40, 0,5mM DTT, protease inhibitor). 
Lysed cells were then spin 2300 rpm and the cytoplasmic fraction was collected 
as supernatant; the pellet was washed twice in Buffer A  and finally resuspended 
in Buffer B (Buffer A supplemented with 0,5% deoxycholate) to collect the 
nuclear fraction . 
Purity of nuclear and cytoplasmic fractions was assessed by immunoblotting for 
PARP and Hsp90. 
RNA EXTRACTION AND qRT-PCR 
RNA extraction was done using UPzol (biotech rabbit) according to 
manufacturer’s protocol; residual DNA was removed by DNAse I digestion 
(Invitrogen) and 500ng of RNA were used to synthesize cDNA using the MMLV 
reverse transcriptase (Invitrogen). 
An equal amount of cDNA from all samples was used to run quantitative real 
time PCR (qRT-PCR) with SYBR Green dye (KAPA SYBER FAST qPCR Bio-Rad iCycle, 
KAPA Biosystem); GAPDH served as an housekeeping gene to quantify viral and 
cellular mRNA abundance. 
The primers sequences used in the qRT-PCR reaction are the following: 




MATR3 FW: 5’-TCT TGG GGG ACC AGC AGT TGG A-3’ 
MATR3 REV: 5’-GCT AGT TTC CAC TCT GCC TTT CTG C-3’ 
GAPDH FW: 5’-CAT GAG AAG TAT GAC AAC AGC-3’ 
GAPDH REV: 5’-AGT CCT TCC ACG ATA CCA AAG-3’ 
US_HIV FW: 5’-CTG AAG CGC GCA CGG CAA-3’ 
US_HIV REV: 5’-GAC GCT CTC GCA CCC ATC TC-3’ 
MS_HIV FW: 5’-TCT ATC AAA GCA ACC CAC CT-3’ 
MS_HIV REV: 5’-CGT CCC AGA TAA GTG CTA AG-3’ 
The primer set for US_HIV amplifies the 5’UTR-Gag region while the one for 
MS_HIV amplifies the Tat-Rev exon. 
HIV-1 REPLICATION KINETICS 
Jurkat cells or PHA-activated primary PBLs were infected with 40-70 ng of 
replication competent HIV-1 for 3 hours (or overnight) at 37°C; cells were then 
washed twice to remove unbound viral particle and cultured in RPMI 10% FBS 
(supplemented with 20U/ml of IL2 for PBLs). 
Every two days supernatant from infected cultures was collected and viral 
particle production was quantified by p24 ELISA (Retrotek or Innogenetics). 
LRAs TREATMENT ON PBL FROM HEALTHY DONOR 
Resting primary PBLs were isolated from healthy donors’ peripheral blood and 
cultured in RPMI containing 10% heat inactivated FBS and IL2 (20U/ml). 
6x10^6 cells were left untreated or stimulated for 3 and 6 days with the 
following drugs at the indicated concentration: 
- Disulfiramin 0,5uM 
- SAHA 0,5uM 
- Romidepsin 0,0175uM 
- JQ1 (0,5uM) in combination to Ingenol B (10nM) 




PHA (5ug/ml) was used as a positive control for cellular activation. 
3 and 6 days post treatment the cells were lysed in Laemmli buffer to collect the 
protein extract. 
LRAs TREATMENT ON J-LAT 
2x10^6 J-Lat 8.4 or J-Lat 6.3 cells were left untreated or stimulated with the 
following drugs at the reported concentrations: 
-SAHA (0,5uM- 1uM- 1,5uM) 
-disulfiramin  (5uM) 
-Ingenol B (0,4uM) 
-JQ1 (0,5uM) 
-Romidepsin (0,006uM - 0,0175uM - 0,026uM) 
-TNFa (30ng/ml) 
48 hours post treatment culture supernatant was collected and cells were lysed 
in UPzol, in Laemmli buffer or analysed by FACS. 
The induction of transcription at the LTR viral promoter was evaluated by both 
GFP expression at the cytofluorimeter and RT-qPCR for the US-HIV mRNA nor-
malized to GAPDH. 
Viral particles in the supernatant were quantified by p24 ELISA. 
FACS ANALYSIS 
J-Lat cells were fixed in 4% PFA for 10 minutes, washed twice with PBS and 
analysed by BD FacsCalibur to check GFP expression. 
FACS analysis on primary resting PBLs were done by MACSQuant Analyzer. 
Samples preparation was done as following: cells were fixed in 4% PFA for 10 
minutes, washed twice in PBS and permeabilized in Permeabilization Buffer ( 
0,5% triton-X, 20mM Hepes pH 7.4, 50mM NaCl, 3mM MgCl, 300mM sucrose) to 
allow intracellular staining with anti-FLAG and anti-p24 antibodies.  




After intracellular staining cells were washed in PBS 0,1% tween and stained for 
surface markers (CD3, CD4, CD69, HLA-DR).  
HIV+ PATIENTS 
Seven HIV-1-infected individuals were selected at the St-Pierre Hospital (Brus-
sels, Belgium) on the basis of the following criteria: all volunteers were treated 
with cART for at least 1 year, had an undetectable plasma HIV-1 RNA level (20 
copies/ml) for at least 1 year and had a level of CD4+ T lymphocytes  higher than 
300 cells/mm3 of blood. Characteristics (age, CD4+ T cell count, CD4+ nadir, anti-
viral regimens) of each patient are presented in Table 1. 
Ethical approval was granted by the Human Subject Ethics Committees of the 
Saint-Pierre Hospital (Brussels, Belgium). All individuals enrolled in the study pro-
vided written informed consent for donating blood. 










QUANTIFICATION OF CELL-FREE HIV RNA IN CULTURE MEDIA OF PATIENTS 
CELLS 
CD8+ depleted PBMCs were isolated from blood of HIV+ patients. 
6x10^6 cells were cultured in LGM-3 Growth Medium (Lonza) and treated with 
the following drugs at the indicated concentrations: 
- Disulfiramin 0,5uM 
- SAHA 0,5uM 
- Romidepsin 0,0175uM 
- JQ1 (0,5uM) in combination to Ingenol B (10nM) 
Anit-CD3-anti-CD28 antibodies were used as a positive control for cellular 
activation. 
Three and six days after treatment, culture supernatants from patient cell cul-
tures were collected for RNA extraction using QIAamp Viral RNA Mini kit 
(Qiagen). HIV-1 RNA levels were quantified using the Generic HIV Charge Viral kit 
(Biocentric) according to the manufacturer’s instructions (detection limits of 110 
HIV-1 RNA copies/ml or 300 HIV-1 RNA copies/ml depending on tested super-
natant volumes). 
QUANTIFICATION OF CELL-ASSOCIATED HIV RNA FROM PATIENTS SAMPLES 
Total RNA was isolated from patient’s CD8+- depleted PBMCs using the Boom 
isolation method (22). 
The RNA was treated with DNase (DNA-free kit; Ambion) and reverse transcribed 
using random primers and SuperScript III reverse transcriptase (all from Invitro-
gen). Cell-associated HIV RNA was quantified using a qPCR assay specific for the 
HIV gag region (23). The amounts of HIV-1 RNA were 
normalized to total cellular inputs, which were quantified in separate qPCR as-
says, using the detection kit for 18S ribosomal RNA (Applied Biosystems, Foster 
City, CA), and were expressed as the number of copies per microgram of total 
RNA. 
 





Typically three independent experiments in triplicate repeats were conducted for 
each condition examined. Average values are shown with standard deviation and 
p-values, measured with a Student’s t-test. Only significant values are indicated 
by the asterisks above the graphs (p<0.01 = ** highly significant; p<0.05 = * sig-
nificant). Data from patients were analysed using paired, non-parametric Wil-
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